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ABSTRACT
The release of RNA-containing extracellular vesicles (EV) into the extracellular milieu has been demon-
strated in a multitude of different in vitro cell systems and in a variety of body fluids. RNA-containing EV
are in the limelight for their capacity to communicate genetically encodedmessages to other cells, their
suitability as candidate biomarkers for diseases, and their use as therapeutic agents. Although EV-RNA
has attracted enormous interest frombasic researchers, clinicians, and industry,we currently have limited
knowledge on which mechanisms drive and regulate RNA incorporation into EV and on how RNA-
encoded messages affect signalling processes in EV-targeted cells. Moreover, EV-RNA research faces
various technical challenges, such as standardisation of EV isolationmethods, optimisation ofmethodol-
ogies to isolate and characterise minute quantities of RNA found in EV, and development of approaches
to demonstrate functional transfer of EV-RNA in vivo. These topics were discussed at the 2015 EV-RNA
workshop of the International Society for Extracellular Vesicles. This position paper was written by the
participants of the workshop not only to give an overview of the current state of knowledge in the field,
but also to clarify that our incomplete knowledge – of the nature of EV(-RNA)s and of how to effectively
and reliably study them – currently prohibits the implementation of gold standards in EV-RNA research.
In addition, this paper creates awareness of possibilities and limitations of currently used strategies to
investigate EV-RNA and calls for caution in interpretation of the obtained data.
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Introduction
Extracellular vesicles (EVs), including exosomes and
microvesicles, are released into the extracellular space
by many cell types. EVs carry a repertoire of bioactive
molecules, including proteins, nucleic acids, lipids and
carbohydrates.[1] Their role has been repeatedly high-
lighted in cell-to-cell communication and lately they
have been implicated in the progression of several
diseases, including neurodegenerative, cardiovascular
and infectious diseases as well as cancer.[2–6] EVs are
present in various body fluids and since the molecular
content of EVs reflects the type and activation status of
their parent cell, they are regarded as potent biomar-
kers for disease.[5,7,8] Additionally, EVs are being
explored as delivery vehicles for therapeutic purposes.
In the last 10 years it has become established that EVs
contain RNA molecules, and thereby represent a vehi-
cle through which cells may transfer genetically
encoded messages to other cells. Although other extra-
cellular carriers of RNA also exist, the purpose of this
article is to highlight particularities in the study of EV-
associated RNA. Current research in the EV field aims
to characterise the RNA content of EVs and the details
of its delivery in vitro and in vivo. Although this field
has attracted enormous interest spanning basic
research, clinics, and industry, understanding of many
aspects of the formation and function of RNA-contain-
ing EVs remains elusive. A lack of standardisation with
regard to EV purification and characterisation of their
molecular contents, as well as technical difficulties in
unequivocally demonstrating that EV-RNA is a causa-
tive agent in EV-mediated effects on target cells, are
among the present challenges to this field.
Following up on the first workshop organised by the
International Society for Extracellular Vesicles (ISEV)
on “Extracellular Vesicle RNA” (New York, 2012),[9]
the society recently organised a second workshop to
address the question: “EV-associated RNA: is there a
purpose?”. This workshop, held in September 2015 in
Utrecht, the Netherlands, brought together 70 interna-
tional experts in the field – including principal inves-
tigators, postdocs, and PhD students as well as
representatives from industry – to share knowledge
and technical expertise on how to address the nature
and function of EV-associated RNA.
Below, we report on the topics that were addressed
during the workshop and substantiate them with refer-
ences to recent literature. We raise awareness of var-
ious factors affecting EV-RNA characterisation (e.g. EV
purity and biases in RNA sequencing methodologies),
discuss the heterogeneity in RNA content of EV,
describe both active and passive RNA sorting processes
which have been suggested to determine the RNA
content of EVs, and conclude that providing undispu-
table evidence that RNA mediates EV-induced effects
remains difficult with currently available methodolo-
gies. In reporting this discussion we provide research-
ers from both inside and outside of the EV community
with a critical overview of the current status of the EV-
RNA research field and an outlook to future challenges.
1. Purification of EVs prior to EV-RNA isolation
1.1. New insights in the heterogeneity of EV and
their RNA content
At the time of the previous ISEV workshop on EV-
RNA in 2012, the research field had already recognised
the heterogeneous nature of vesicles present in the
extracellular environment.[10] The typically presented
classification divided EVs into two subtypes: EVs with
diameters ≤100–150 nm and buoyant densities of 1.11–
1.19 g ml–1 that are formed inside multivesicular bodies
(MVBs) were defined as exosomes, while EVs with
diameters ranging up to 1000 nm which presumably
bud from the plasma membrane were variably called
ectosomes, microvesicles, microparticles, or large onco-
somes. The exact definitions varied widely between
publications and overlap in sizes between these two
categories was not generally commented on.
It is clear that these categories represent an over-
simplification. For instance, EVs formed directly at the
plasma membrane can share several biophysical prop-
erties with EVs formed in MVBs, such as size, isolation
by high-speed ultracentrifugation, and floatation in
density gradients at the expected 1.11–1.19 g ml–1
position.[11] Thus, EVs in the small size range likely
represent vesicles heterogeneous in origin, with an
unknown portion coming from MVBs. The definition
of larger EVs is even less precise, and these vesicles
comprise a wide range of membrane-enclosed entities.
Indeed, it is not yet clear how to divide EVs into their
relevant subtypes, or even how many functionally dis-
tinct subtypes there may be.
Several laboratories have now started characterising
the protein composition of subtypes of EVs. EV sub-
types have been isolated by a number of means, includ-
ing recovery at different centrifugation speeds, through
different filters, at slightly different positions in density
gradients, via immuno-isolation by different surface
molecules, or by flow cytometric sorting.[12–20]
Extensive comparison of these results (obtained with
EVs from different cellular sources) has not yet been
performed, but the available data already indicate that
some proteins classically regarded as “exosome
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markers” are in fact present in all different EV types
(e.g. heat shock proteins, flotillins and major histocom-
patibility complex molecules). Such intracellular or
membrane-associated proteins can therefore be used
as EV markers, but will not define the nature of the
EV subtype analysed. Furthermore, within the “exo-
some” population, subsets could be defined based on
combinations of protein markers which colocalise or
are co-depleted in vesicles enriched in endosomal pro-
teins vs. plasma membrane proteins.[12,19] Given the
difficulty of separating subtypes of EVs with ultracen-
trifugation, Thery’s group has recently chosen to refer
to vesicles sedimenting at 100,000 g as “small EVs”
(sEVs) rather than exosomes, those pelleting at inter-
mediate speed (lower than 20,000 g) as “medium EVs”
(mEVs, including microvesicles, ectosomes) and those
pelleting at low-speed (e.g. 2000 g) as “large EVs”
(lEVs, including large fragments of the releasing cell
and large apoptotic bodies). EVs of small size are also
enriched in many studies by the use of filters of small
pore size (100 or 220 nm). These definitions are per-
haps less biologically meaningful but far more experi-
mentally tractable than the previous exosome/
microvesicle definitions, since EV size, often deter-
mined by nanoparticle tracking analysis or electron
microscopy, is frequently reported in EV studies.
Until we have stringent and robust methods for separa-
tion and characterisation of MVB vs. plasma mem-
brane-derived EVs, the proposed nomenclature could
increase clarity of discussion and ease of cross-referen-
cing between studies. However, consensus has not been
reached on this issue and the current nomenclature is
therefore maintained until further notice.
It is still unknown whether all EVs contain RNA and
how diverse the RNA content of different EV subpopu-
lations may be. Various studies indicate that the RNA
content of EVs varies among cell types and among EV
subpopulations. For example, miR-145 is present at very
low levels in HepG2 cell-derived large EVs, whereas the
same miRNA is present at significant levels in both large
and small EVs derived from A549 cells.[21] In immune
cells, the miRNA content of EVs was shown to differ by
immune cell type when comparing EVs from B- or T-cell
lines and primary dendritic cells (DC).[22] Another
remarkable example of EV-RNA heterogeneity is the
sex difference observed in the miRNA content of urinary
EVs.[23] With regard to the RNA content of different
EV subpopulations, it was shown that EV populations
that separated into different fractions based on pelleting
at different g-forces differed in RNA content.[24] Even
EVs sedimenting at the same g-force are heterogeneous
in nature and may be further separated based on differ-
ences in migration velocity in density gradients; recent
data indicate that EV subpopulations isolated based on
this parameter differ in both protein and RNA content.
[20] In a recent study, the copy number of a given
miRNA molecule was suggested to be on average lower
than one per vesicle/particle in an EV sample.[25] If we
assume that all of the detected miRNA species were
indeed EV-associated and that EV quantifications were
accurate, one explanation for these data is that specific
miRNA sequences could be restricted to specific sub-
types of EVs. This scenario would be consistent with a
high specificity in delivery of RNA molecules to target
cells (see also section 4.1.2).
The presence of extracellular RNA circulating in
non-EV-associated forms, for instance in large protein
(e.g. Argonaute 2 (AGO2)) or lipoprotein complexes,
adds another layer of complexity to the analysis of EV-
RNA. These complexes have been shown to co-isolate
with EVs during common isolation procedures such as
ultracentrifugation [26] (see section 1.3.1). Thus it is
possible that, of the numerous types of nucleic acids
described “in EVs” in the existing literature, some are
contained within specific subtypes of EVs and some are
perhaps not present in EVs at all but exclusively in
other carriers which co-isolate. A particular point of
concern is the potential carryover of extracellular RNA
originating from foetal bovine serum used in cell cul-
ture media, which, if not effectively removed, affects
the analysis of EV-RNA released by the cell of interest.
[27,28] This urges the need for including control iso-
lates from non-conditioned culture medium in the
RNA analysis.
1.2. Update on EV purification methods and
effects on EV-RNA analysis
Participants of the meeting expressed their concern
about the enduring lack of standardisation with regard
to the collection, storage, and processing of EV-con-
taining fluids, and the large diversity of methods used
for EV isolation. Each of these factors influences not
only the type and number of EV isolated, but also the
level of contamination with non-EV-associated RNA in
the obtained EV preparation.
Though differential centrifugation remains the most
commonly used method of EV isolation, several differ-
ent techniques have risen in prominence since the 2012
meeting on EV-RNA (Figure 1). Pros and cons of
commonly used EV isolation techniques have been
reviewed more elaborately elsewhere (see for example
[29,30]), but are briefly summarised below. Differential
centrifugation can be followed by density gradient
ultracentrifugation to separate low-density EVs from
high-density protein aggregates that often contaminate
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EV ultracentrifugation pellets. Size exclusion chroma-
tography (SEC) is now a more widely used technique
for EV isolation. It can be used for low volume samples
and allows separation of EV from the bulk of soluble
proteins. However, since separation is purely based on
particle size, contaminating particles in the EV size
range such as (lipo)protein complexes may be co-iso-
lated. Immuno-affinity capture presents an alternative
method for EV isolation. The method can yield pure
EV subpopulations, but is highly influenced by both
the choice of affinity reagent and the ligand density on
different EV types. In addition, various commercial kits
that make use of volume-excluding polymers such as
polyethylene glycol (PEG) are currently available for
rapid EV isolation from culture media or body fluids.
However, such polymers co-precipitate protein (com-
plexes) that contaminate EV isolates. It was highlighted
during the meeting that the different EV isolation
techniques are based on different principles and will
therefore enrich for different subpopulations of vesi-
cles. In addition, these methods co-isolate contami-
nants (e.g. protein complexes and lipoproteins) to
Figure 1. Schematic illustration of commonly used EV isolation techniques. (a) Differential centrifugation is the sequential pelleting
of particles with decreasing sedimentation coefficients. Typically 2000 g is used to pellet large EVs, 10,000–20,000 g to pellet
middle-sized EVs (green), and finally ~100,000 g to pellet the smallest EVs (different EV subpopulations are indicated in grey and
orange). At these high g-forces, complexes of soluble proteins (black dots) may also sediment. (b) Lipids have a density that is
approximately 1 g cm–3, while proteins and RNA have a higher density (>1.3 g cm–3). Therefore density gradients can be used to
separate subpopulations of EVs with different ratio of lipids, RNA, and proteins. Moreover, these gradients can be used to purify
vesicles away from soluble proteins, RNA, and protein–RNA complexes as the latter structures will not float at the same density as
the lipid containing EVs. (c) Size exclusion chromatography separates particles based on their size, by trapping the smaller
molecules (such as proteins and protein complexes) in the pores. The larger molecules (such as EVs) are too large to enter the
pores and will elute first. (d) Precipitation of EV from cell culture medium or body fluids is based on volume-excluding polymers
such as polyethylene glycol (PEG) with which biological materials such as proteins and EVs are precipitated from the solution. (e)
(Immuno-)affinity capture isolates vesicles using beads coated with antibodies or proteins (such as heparin) with affinity for an EV
transmembrane protein. Vesicles displaying the protein of interest will bind to the beads and can thereby be isolated from the
vesicle-containing solution.
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different degrees. Combinations of techniques, such as
density gradient centrifugation followed by size exclu-
sion or immuno-affinity capture, are being used more
frequently. Moreover, comparative studies on different
techniques including SEC for isolation of pure EV
populations have been published.[31] There are few
data available on the impact of different EV isolation
methods on EV-RNA yield and purity.[32,33] In one of
these studies, RNA was obtained from EVs isolated by
ultracentrifugation, density gradient centrifugation,
and two commercially available precipitation-based
kits.[32] Although three to eight times less protein
and fewer particles were detected compared to the
kit-based EV isolation, density gradient-based isolation
of EV yielded the purest EV population, as assessed by
immunogold electron microscopy and Western blots.
Importantly, with some commercial kits 100-fold more
RNA could be isolated compared to the density gradi-
ent method, albeit the technical reproducibility of the
kit-based isolations was often low. This study high-
lights the trade-off of yield vs. purity: it is clear that
although some isolation techniques give higher yields
of RNA, it comes at the cost of lower purity, which can
affect conclusions drawn from RNA analysis. Which
isolation method is optimal and which impurities are
acceptable depends on the research question and
downstream analysis; in the discovery phase of EV-
RNA biomarkers, when association of disease markers
with EV still needs confirmation, contamination of EV
isolates may lead to erroneous conclusions. Also stu-
dies to unravel the role of EV-RNA in (patho)physio-
logical processes require pure EV populations.
However, when detecting established EV-RNA-based
biomarkers in low volume patient samples, increased
protein/lipid/RNA yields at the cost of lower EV purity
may be acceptable. In addition, preferences for specific
EV isolation methods will depend on the type and
volume of the starting material, the number of samples
to be analysed, and the logistical setting and laboratory
infrastructure.
At this stage, the EV-RNA community would cer-
tainly benefit from more comparative studies on the
effects of EV isolation strategies on EV-RNA yield and
identity, and from studies that critically evaluate the
potential use of kit-based assays for clinical
applications.
1.3. Isolation of EVs from different sources prior to
EV-RNA isolation and characterisation
EVs are isolated from a variety of different sources,
including body fluids with highly variable composition
(e.g. plasma, serum, milk, urine, nasal washes,
cerebrospinal fluid and saliva), cell culture media of
cell lines and primary cells, and tissues or tumours.
Additionally, EVs from various different species are
being investigated, ranging from humans to microbes.
It is therefore difficult to provide general recommenda-
tions for EV isolation and characterisation. For several
body fluids, considerations and recommendations were
provided after the previous EV-RNA meeting in 2012.
[34] Although these are still valid, we have extended
our knowledge on the complexity of body fluids and
how this affects EV isolation. Although no gold stan-
dards can be provided yet for isolation of EV from the
different fluids, recent data progressed our understand-
ing of the nature of contaminants in EV isolates from
different body fluids and of pre-analytic variables that
affect the type or purity of isolated EV (see for example
[35–40]). The non-EV contaminants found in EV pre-
parations differ substantially between body fluids; EVs
from certain fluids (e.g. nasal fluid, saliva, milk and
urine) can contain bacteria-derived material. Other
fluids may contain substantial amounts of biofluid-
specific contaminants, such as Tamm–Horsfall glyco-
protein in urine or glycosaminoglycans/proteoglycans
in synovial fluid samples. Standardised and optimised
pre-analytical conditions for EV isolation should there-
fore be carefully determined for each of the biological
fluids separately.
Blood plasma is the most commonly used source of
EVs in EV-RNA analysis studies. It represents a very
complex fluid from which EV isolation remains challen-
ging. Below, we highlight recent developments in research
on EVs in plasma to exemplify the challenges we face
when performing EV-RNA analysis in body fluids.
1.3.1. EV-RNA isolation from blood plasma
Both serum and plasma are used for EV research and
biomarker discovery. Serum contains high numbers of
EV released by platelets in response to coagulation.
Although platelet-derived EV may be considered as
biomarkers for a variety of pathological processes,[41]
there is limited knowledge on differences in the RNA
content of EV isolated from serum and plasma samples
obtained from the same donor.[42] Plasma mainly
contains EV originally present in circulating blood
and is therefore the preferred source when studying
(patho)physiological functions of EV. Anticoagulation
of blood samples has a major impact on the number
and composition of isolated EVs because the efficiency
of this process affects the number of platelet-derived
EVs in plasma preparations. The recommendation of
the International Society on Thrombosis and
Haemostasis is the use of citrated platelet free plasma
[43] for EV isolation and analysis. However, acid-
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citrate dextrose (ACD) has been shown to be superior
to citrate with respect to preventing in vitro generation
of platelet EVs within the blood collection tube, and is
compatible with downstream RNA analysis.[44] Thus,
using ACD as anticoagulant ensures isolation of EVs
that are present in circulation in vivo (and not those
released in vitro by platelets in the blood collection
tube).
Protein complexes may co-purify with EVs from
blood plasma and may also mimic EVs during enu-
meration of vesicles.[26,45] These protein complexes
include RNA-binding proteins such as AGO proteins,
[26,46] which form complexes with miRNAs.
Importantly, lipoproteins can also contaminate blood-
derived EV preparations. Both LDL and HDL were
shown to transport miRNA,[47] which may be co-iso-
lated with EV-associated RNA. In addition, EV-sized
chylomicrons are present in platelet-free blood plasma
samples, and can confound EV enumeration, most
prominently in the postprandial state.[39]
Postprandial state also affects the levels of HDL parti-
cles that co-purify with EVs.[48] HDL cannot be dis-
criminated from EVs based on buoyant density (1.06–
1.20 g cm–3), but may in theory be separated from EV
by SEC or ultracentrifugation because of their much
smaller size (10 nm). Other lipoproteins such as VLDL
and chylomicrons may be more effectively removed
using a density gradient as they have a density
<1.06 g cm–3, but are similar in size to EV (≥60 nm).
SEC was shown to allow separation of EV from con-
taminating proteins and HDL present in platelet concen-
trates.[49] However, a more recent study proposes that
EV-mimicking LDL particles are present in blood plasma
at almost one order of magnitude higher concentration
than EVs and suggests that they cannot be fully removed
from EV preparations by any of the known EV isolation
and purification methods.[39] As a result, detection of
blood plasma-derived EVs based on particle counts
might strongly overestimate EV numbers, and proteomic
or nucleic acid analysis of these EV preparations may
contain significant contamination from non-EV sources.
1.4. The importance of knowledge exchange and
correct reporting
The participants stressed the importance of setting up a
forum on which key issues with regard to best practice
for fluid collection, storage, processing, and for EV
isolation methodologies can be discussed for each indi-
vidual fluid. Arising from discussions at the Utrecht
EV-RNA workshop, an initiative to meet this need was
taken at the ISEV meeting in Rotterdam 2016, where
the “Experts Meet” sessions were introduced. In each of
these sessions, researchers with hands-on expertise on
working with particular body fluids (blood, milk,
urine) met and discussed recent developments. This
may in the future lead to renewed and refined guide-
lines and also could fuel collaborative research in
which several labs analyse the same samples to further
develop standardised protocols. Ideally, researchers
should engage with biobanks to ensure that collection
of new samples will occur using the best possible pro-
tocols for collection and storage of body fluids. It was
also highlighted during the meeting that methods sec-
tions of EV publications usually contain too few details
to be able to reproduce the obtained results. Currently
there is a strong need to develop tailored checklists for
descriptions of collection methods, storage conditions,
and EV purification methods, which will improve best
practices and reproducibility of published results.
2. Analysis of the quantity and diversity of EV-
RNA
Several different types of small and long RNAs have
been identified in EVs (reviewed in [50]). The EV
isolation method of choice determines the yield and
purity of EV preparations, and as a consequence,
the quantity and quality of EV-RNA.[32,51]
Measuring the quantity and integrity of EV-asso-
ciated RNA is challenging due to low RNA quanti-
ties and a lack of standards, such as those
established for cell RNA. Below, we address topics
discussed at the workshop concerning quantification
of EV-RNA and reliable assessment of the nature of
EV-associated RNAs.
2.1. Assessing EV-RNA quantity
The study of EV-RNA poses challenges both shared
with and distinct from the study of cellular RNA. Many
of these stem from the fact that researchers studying
EV-RNA are typically working with very small quan-
tities of RNA relative to quantities found in cells; this is
generally true for EVs from in vitro cell cultures but
especially pertinent for those harvested from patient or
animal samples, where large sample volumes may be
difficult to obtain. Even the quantification of these
small amounts of RNA can be non-trivial. In contrast
to cellular RNA, in which intact ribosomal RNA dom-
inates the pool of RNA and detection signal, EV sam-
ples are mostly devoid of intact large and small
ribosomal RNA subunits. As a result, the required
RNA quantity for specific analysis methods (e.g.
sequencing, microarrays or quantitative reverse tran-
scription polymerase chain reaction (RT-qPCR)) does
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not necessarily match respective recommendations for
cellular RNA samples. RNA quantification methods
have recently been compared and evaluated by
Aranda et al. [52]. In this section we review RNA
quantification methods discussed at the workshop and
comment on their suitability for use in EV-RNA stu-
dies (summarised in Table 1).
The Nanodrop spectrophotometer family (Nanodrop
1000, 2000, or 2000c; Thermo Fisher Scientific,
Wilmington, USA) measures microliter volumes of
RNA based on UV-absorbance that is accurate in the
range of 3 µg µl–1 to 2 ng µl–1. As RNA obtained from
EV preparations is typically present in less than 2 ng µl–1
concentration, Nanodrop is not a suitable method for
measuring EV-RNA unless working with a highly con-
centrated sample.
The Qubit RNA HS (high sensitivity) assay (Thermo
Fisher Scientific) is highly specific for RNA but has a limit
of >0.2 ng µl–1 when using the maximum volume for the
kit (20 µl of sample). Therefore, it is not convenient for
measuring EV-RNA unless using a large volume of sam-
ple or a relatively concentrated sample. However, it was
shown that with the addition of spike-ins to bring sample
RNA concentration above the minimum, the Qubit RNA
HS assay is able to quantify small amounts of RNA with
high specificity, down five-fold (to 1 ng) from the assay’s
previous lower detection limit.[53] This technique may
be particularly useful if it is necessary to measure RNA in
the presence of DNA contamination.
With a lower detection limit of 50 pg µl–1, the
Bioanalyzer Pico chip (Agilent Technologies, Foster city,
USA) is one of the most sensitive RNA quantification
methods currently available. Notably, it requires only 1 µl
of sample and gives electrophoresis-like length profiles
which are useful for estimating the size distribution of
RNA in EV samples. However, the chip and the software
based on the RIN algorithm are designed to assess quality
based on the large ribosomal subunits, which are not
present at the same level in EVs. It should also be noted
that peaks of mRNAs and long RNAs are less well dis-
cerned, as they are distributed over a greater range of
transcript lengths. The small RNA chip (Agilent
Technologies) may therefore be more relevant for asses-
sing EV-associated RNA content and length. It has been
reported that RNA quantification by chip-based systems
is in general error prone.[54] In both Pico and small RNA
chips the RNA concentration is determined relative to a
supplied RNA ladder and internal marker peaks, which
can show variability between measurements if the chip is
not prepared meticulously. Occasionally, aggregates in
the RNA dye can cause peaks in the electrophoresis
profiles, leading to quantification errors. Furthermore,
the Pico assay is sensitive to differences in salt concentra-
tion, which can vary between different RNA isolation kits
and can also be affected by DNase treatment. The Nano
chip is less sensitive to salt but has a quantitative detection
limit of 25 ng µl–1 (qualitative lower limit 5 ng µl–1). In
addition, contaminating DNA in EV-RNA isolates is
detected in any Bioanalyzer 2100 chip, as their detection
strategy employs a dye that is not specific to RNA.
Despite these caveats, the Bioanalyzer remains a popular
method to quantify EV-RNA, particularly when it is
desirable to obtain a size profile of RNA present in the
sample.
When access to specialised RNA quantitation equip-
ment is restricted, an alternative is to use the Quant-iT
RiboGreen RNA Assay kit (Thermo Fisher Scientific).
This assay is based on a nucleic acid-specific fluores-
cent dye that can be used to quantify RNA with a linear
detection range of 1–200 ng using any standard
Table 1. Suitability of RNA detection methods for quantification of EV-RNA.
Method Lower detection limit
RNA vs.
DNA
specific? Remarks
Nanodrop spectrophotometer
family (Nanodrop, Thermo
Fisher Scientific)
3 µg µl–1 to 2 ng µl–1 range for microliter
volumes of RNA
No Not generally suited for measuring EV-RNA due to high lower
limit for detection.
Qubit RNA HS (high
sensitivity) assay (Thermo
Fisher Scientific)
>0.2 ng µl–1 (initial sample concentration if
using the maximum volume for the kit,
20 µl of sample)
Yes Not generally suited for measuring EV-RNA due to high lower
limit for detection.
Bioanalyzer Pico chip (Agilent
Technologies)
50 pg µl–1 No Most sensitive quantification method for total RNA, but prone to
error.
Most relevant for assessing total RNA content and length distribution.
Bioanalyzer small RNA chip
(Agilent Technologies)
50 pg µl–1 of purified miRNA or 10 ng µl–1
of total (cell) RNA in size range of 6–150 nt
No Similar properties as Pico chip.
Useful for resolving miRNA from tRNA and other small RNA
species.
Quant-iT RiboGreen RNA Assay
kit (Thermo Fisher Scientific)
Detection range of 1–200 ng (sample
diluted to 1 ml)
No Less sensitive to contaminants, such as protein and phenol
chloroform.
Quantitative reverse
transcription polymerase chain
reaction (RT-qPCR)
1 fg (~2500 copies for mRNA) of a
particular transcript
No Most sensitive quantification method overall but does not
analyse total RNA, must select primers specific to target
transcript(s) and validate to check for off-target amplification.
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fluorescence microplate reader. This assay is sensitive
to DNA contamination, but less sensitive to protein
and phenol chloroform. The use of a standard curve
that can be adjusted for low input RNA and the custom
of running samples in triplicate improve suitability for
low input samples.
Finally, RT-qPCR was used by various participants of
the workshop to measure transcript abundances in EV-
RNA preparations. This technique quantifies levels of a
particular nucleic acid transcript in a sample by measur-
ing its increase in concentration over time (using fluor-
escent nucleotides or a fluorescent probe) when subjected
to exponential amplification by PCR.[55] Although this
method does not directly measure total RNA, it is extre-
mely sensitive, able to detect 1 fg or ~2500 copies of a
given transcript in an optimised system.[56] Given the
often material-limited nature of EV-RNA research, mea-
suring a panel of individual transcripts by RT-qPCR as a
proxy for total RNA content may be more experimentally
feasible than any other quantificationmethod (see section
2.4 on normalization strategies and reference transcripts
for further discussion). RT-qPCR is sensitive to DNA
contamination, though this can be minimised by good
experimental practice, such as running a gel to verify a
single amplicon of the expected size and designing pri-
mers over exon-exon junctions in the case of mRNA.
In summary, sensitive techniques such as Agilent
Bioanalyzer pico chip and the Quant-iT RiboGreen
RNA Assay are far more suitable for EV-RNA quanti-
fication than the Nanodrop. Detection of the levels of
particular transcripts by highly sensitive RT-qPCR may
be used as a proxy for total RNA quantity in samples
containing a very low amount of RNA. Most techni-
ques, with the exception of the Qubit RNA HS Assay,
are also sensitive to DNA contamination. We therefore
recommend pre-treatment of samples with DNase for
accurate RNA quantitation (see section 2.2.1.2 for
further discussion).
2.2. Assessing EV-RNA quality
Isolation of intact (non-degraded) RNA is of great
importance in quantitative gene expression profiling
experiments. RNA may be degraded in many ways:
by enzymes, namely ribonucleases (RNases), which
are both ubiquitous and extremely stable; by mechan-
ical stress introduced by freezing, thawing or centrifu-
gation; by base-catalysed hydrolysis; by heat, especially
in the presence of divalent cations; and by UV damage.
Exposure to any of these agents can cause RNA damage
and influence the results obtained by downstream
quantitative applications.[57] This risk becomes more
pertinent when working with small quantities of RNA,
as it is more likely to become fragmented over the
course of many handling steps required for the isola-
tion procedure. However, it should also be taken into
account that EVs may contain processed fragments of
longer RNAs that are biologically relevant. In addition
to RNA integrity, another important quality measure is
the purity of RNA. The following sections will deal
with assessment of EV-RNA purity and integrity.
Methods and considerations for these experiments are
summarised in Table 2.
2.2.1. Experimental artefacts and contaminants
affecting EV-RNA analysis
2.2.1.1. Non-EV associated RNA and lab-derived con-
taminations. A major source of contamination is the
presence of other RNA-containing structures in EV
samples. Potential contaminants include
Table 2. Methods for determining EV-RNA purity and integrity.
Method Use Pros Cons
Agilent Bioanalyzer chips Integrity ● Small volume required
● Highly sensitive
● Total length profile of RNA
● Not suited for assessing small RNA integrity
● Assessment based on intact 18S/28S rRNAs gener-
ally depleted from EVs
● Sensitive to contaminants such as DNA
Next generation
sequencing
Integrity &
purity
● Detects fragmentation, for example as 3′ bias in mRNA
reads after poly-A selection
● Detects presence of foreign genetic material (e.g.
derived from foetal bovine serum)
● Erroneous assessment of fragments in the case of
highly modified RNA types
● Long reads (i.e. PacBio) most useful but require lots
of material
RT-PCR and derivatives
(i.e. 5′/3′ RACE)
Integrity ● Robust and sensitive, can map exact sites of
fragmentation
● Analysis of single transcripts only
Northern blot Integrity ● Robust and sensitive
● Simultaneous detection of full length and fragmented
stretches of the same RNA
● Analysis of single transcripts only
● Time-consuming
Proteinase-nuclease
protection assay
Purity ● Rigorously determine that RNA is present in EV lumen ● Leftover nucleases may still be active at point of
vesicle lysis
Blank run Purity ● Test kits and reagents for nucleic acid contamination —
Picogreen Purity ● Test for presence of dsDNA ● Not DNA-specific in samples with RNA concen-
trations over 130 ng ml–1
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ribonucleoprotein complexes (RNPs), viral particles,
and lipoproteins (HDL and LDL), which may originate
either from the EV source or from foetal bovine serum
used in cell culture media.[27,28] Steps taken to
increase stringency of the isolation protocol, for exam-
ple washing and re-pelleting EVs after centrifugation,
may decrease contamination but cannot fully eliminate
it, since contaminating particles present in the first
pellet may re-pellet together with EVs (see references
in section 1.3.1 for details). RNPs may also in theory
become non-specifically associated with the EV surface,
especially after high centrifugal force is applied to the
sample. To rigorously distinguish between RNA encap-
sulated within EVs from RNA outside EVs, it is critical
to treat EV samples with proteinase and RNase to
disrupt ribonucleoproteins exterior to vesicles (see sec-
tion 3.2.3 for more details). Low RNA inputs can also
amplify the effects of lab-derived contamination, espe-
cially when performing high throughput sequencing.
This was shown both for DNA [25] and RNA [58]
contamination, coming from various sources including
commercial nucleic acid extraction kits and sample
cross-contamination. A blank run can be performed
(e.g. sequencing a pure buffer sample processed similar
to the EV-RNA samples) to control for these possibi-
lities, but in general researchers should be meticulous
when working with EV-RNA and aware of the poten-
tial pitfalls.
2.2.1.2. Are DNA and rRNA naturally associated with
EVs? The question of which RNA components should
be considered as “true” EV-RNA and which as impu-
rities or contaminants has been extensively addressed
during the workshop. The presence of both DNA and
rRNA in EVs, for example, is disputed. Extracellular
DNA is known to be present in various biological fluids
(e.g. plasma and urine) and in culture medium as a
result of necrosis/apoptosis or active cellular secretion
processes,[59] but it is not clear if it is also present
inside EVs. In order to determine if DNA present in an
EV preparation is truly encapsulated in vesicles,
researchers should perform proteinase and DNase
treatments prior to vesicle lysis (compared with
DNase treatment post-lysis) and read out DNA to
demonstrate protection or lack thereof.[60]
If DNA is not the intended object of study, the
presence of DNA in EV-RNA preparations can inter-
fere with downstream analysis. It was mentioned above
that ssDNA and dsDNA could interfere with RNA
signals in the Bioanalyzer small RNA and RNA pico
chips as well as in RT-PCR. Although RNA extraction
kits usually give very low DNA contamination,[61]
many EV-RNA researchers indicated that they
regularly experience DNA contamination in EV-RNA
preparations. It is advisable to test the RNA extraction
kits with or without DNase treatment according to the
desired downstream applications. Especially for down-
stream deep sequencing analysis, it is important to
treat EV-RNA samples with DNase. The most suitable
kit according to workshop attendants was the Ambion
Turbo-DNA free kit (Thermo Fisher Scientific). It
effectively eliminates most DNA, and RNA can subse-
quently be cleaned up from the enzyme and buffer with
beads, which is useful for very low RNA input samples
and ease of handling. Picogreen was suggested as an
assay for detecting DNA contamination, as it is sensi-
tive to dsDNA down to 250 pg ml–1 and selective for
dsDNA over RNA for RNA concentrations less than
130 ng ml–1.[62] Alternatively, in deep sequencing
protocols based on poly-A enrichment, presence of
genomic DNA could be assessed by the percentage of
intronic reads, though this may not hold true for other
protocols.[63]
During the round-table discussions, attendants of
the workshop also discussed the origin of DNA and
rRNA in EV-RNA preparations. It was raised that large
DNA fragments (>3 kb) could elute in EV-containing
fractions obtained by SEC, either due to non-specific
binding to EV or due to similarity in size and molecu-
lar weight. Similarly, large DNA fragments could pellet
at high g-force if they have sufficiently high molecular
weight, or become associated with EVs during centri-
fugation. These considerations may also apply to ribo-
somes present in extracellular fluids and explain the
variable presence of rRNA in EVs in the literature.
Ultimately, demonstration of protection from nucleases
after proteinase treatment is the only way to assert that
a given nucleic acid species is encapsulated in a lipid
membrane structure and not adhered to it or simply
co-isolating.
2.2.1.3. RNA integrity and RNA fragments. Several
methods exist to measure RNA integrity. In most
cases, research groups assess total RNA quality using
Agilent Bioanalyzer chips. The standard metric for
cellular RNA quality, the RNA integrity number
(RIN), determined using Agilent Bioanalyzer chips,
corresponds to the presence and profile of intact 18S
and 28S ribosomal RNA subunits. However, ribosomal
RNAs are generally depleted from EVs, making this
approach ineffective as quality control for EV-RNA.
Next-generation sequencing technologies allowing sin-
gle-molecule RNA sequencing (e.g. Pacific Bio) may be
useful to assess the overall integrity of long EV-RNA;
however, the large quantity of RNA starting material
required for these technologies currently impedes their
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application to analysing EV-RNA. Alternatively, more
classical techniques such as RT-PCR and derivatives
(e.g. 5′/3′ RACE) allow the determination of integrity
for a selected set of RNAs, which could be used as
quality control markers to validate an EV preparation
technique or batch.[64,65] For example, “housekeep-
ing” mRNAs or miRNAs at a range of levels of expres-
sion could serve this purpose.
An interesting question rising in the field is whether
the RNA associated with EVs is fully intact, fragmen-
ted, or specifically processed. There is an increasing
body of evidence supporting the involvement of
ncRNA fragments in many biological processes, includ-
ing gene regulation.[66–69] Small RNA-seq analysis
has indicated that EVs are associated with various
fragments derived from mRNAs and ncRNAs, includ-
ing rRNA, tRNA (also called tRFs, tRNA-derived RNA
fragments), YRNA, snRNA, snoRNA, lncRNA and
vault RNA.[70–74] Many of these fragments even
showed pronounced enrichment in the EVs compared
to their parental cells. The degree of fragmentation of
particular RNAs may also depend on the protection by
encapsulation in the vesicle membrane; for example, in
nematode-derived EVs, full length YRNAs were found
exclusively inside EVs whereas fragments were found
outside EVs.[75]
Currently, there is no definitive proof indicating
whether the RNA fragments found in EVs are formed
by specific processing steps or whether these are arte-
facts induced by handling during the EV-isolation pro-
cedure. Specific RNA cleavage may occur in the
parental cell cytoplasm, prior to enclosure of such
fragments into EVs; alternatively, RNA fragments
may be generated due to processing inside the EVs,
as part of an extracellular maturation process. For
example, EVs containing the enzyme Dicer were
reported to perform cell-independent miRNA biogen-
esis by cleaving pre-miRNAs shuttled into the vesicles.
[76] This remains controversial, as some attendants of
the meeting were unable to detect Dicer or other main
components of the RNA interference machinery in the
vesicle fractions of sucrose gradient-based purifica-
tions, and thus this particular pathway remains to be
explored in more detail.
Artefactual EV-RNA fragments could arise due to
non-specific degradation of ncRNAs after sample collec-
tion or technical inability to amplify the full-length pre-
cursors. Common reverse transcriptase enzymes used in
RNA-sequencing library preparation protocols are
unable to read through highly modified or structured
RNAs such as tRNAs, and fall off, producing what looks
in the analysis like a fragment. However, a recent protocol
based on RNA pretreatment with E.coli AlkB (which
demethylates tRNAs and removes most of the so-called
“hard-stop” modifications responsible for reverse tran-
scriptase fall-off) showed a sharp increase rather than a
decrease in tRNA-derived fragments,[77] which implies
that the presence of these fragments is not necessarily
artefactual. During the meeting it was discussed that
sequencing of EV-RNA using a thermostable group II
intron reverse transcriptase [78] may also improve the
efficiency with which full-length tRNA can be sequenced.
In addition, Northern blotting can be used to distinguish
full length and fragmented stretches of the same RNA,
since this technique is not susceptible to the above men-
tioned biases. Using this method, defined and biologically
relevant fragmentation of YRNA was demonstrated by
applying oligo probes targeting the putative fragment(s)
or full length RNA.[79,80] Additionally, RT-PCR using
various placements of primers along the transcript can be
used to map the RNA fragmentation state. This has for
example been applied for detection of a fragmented form
of 7SL RNA in HIV-1 virus-like particles, using a combi-
nation of S1 nuclease mapping and analysis of RT-PCR
amplicons with primers located inside or outside the
fragment.[81]
2.3. Biases in RNA isolation and high-throughput
RNA sequencing
Due to the enrichment of small RNAs in EV, recent
sequencing studies in the field have largely focused on
the assessment of miRNAs and other small non-cod-
ing RNAs. Though the discussions at the workshop
focused on biases specific to deep sequencing experi-
ments, it is worth emphasising that for all experiments
analysing quantitative gene expression, the RNA
extraction strategy and any biases specific to that
method should be taken into consideration. For
example, the popular RNA extraction reagent TRIzol
has been shown to exhibit strong anti-GC-content
bias in small RNA extraction from low quantities of
total RNA, a caveat which is highly relevant for EV-
RNA researchers working with similarly low RNA
quantities.[82] Sources of bias in RNA extraction
and sequencing discussed in this section are sum-
marised in Table 3.
Downstream of RNA extraction, deep sequencing
analysis of EV-RNA is prone to biases at several dif-
ferent steps in the analysis. First, sequence biases occur
during library preparation, for which many kits are
available. For small RNA, for example, these include
NEBNext multiplex small RNA library preparation kit
(New England Biolab, Ipswich, MA, USA), NEXTflex
small RNA sequencing kit (Bioo Scientific, Austin, TX,
USA), TruSeq small RNA sample preparation kit
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(Illumina, San Diego, CA, USA), and others.
[72,74,83,84] One study presented at the meeting also
used the CleanTag small RNA library kit (TriLink, San
Diego, CA, USA) which has been proposed to reduce
background adapter-dimers that can negatively influ-
ence the analysis of low-input samples. Most small
RNASeq kits require RNAs to be captured by ligation,
rather than priming, and these ligations are prone to
biases.[85,86] Newly developed methods, such as
CATS,[87] 4N adapter-based kits and the NEXTflex
and SMARTer smRNA-Seq kits, have introduced stra-
tegies to avoid adaptor-ligation biases. The type of kit
or protocol used heavily influences library preparation
and the observed RNA profile, as was for example
shown for plasma-derived EVs.[83] One challenge of
deep sequencing analysis is that some “medium” length
non-coding RNAs (e.g. snoRNAs of 60–300 nt) are
difficult to capture either by small RNA sequencing
kits or long RNA sequencing kits, and therefore require
the use of kit-free protocols.
A nearly unavoidable second source of bias is that
introduced due to size selection after cDNA synthesis
and adapter ligation. This is performed in most small
RNA sequencing protocols and thus particularly rele-
vant for small non-coding RNAs. Almost all nucleic
acid purification strategies have some size selectivity.
For example, Zymo Clean & Concentrate kits yield
small RNA with one concentration of ethanol and
long RNA with another; SPRI (solid phase reversible
immobilisation) beads isolate DNA fragments of dif-
ferent lengths according to the bead:DNA ratio, and
even RNA precipitation in different volumes of ethanol
will yield different size distributions in the precipitate.
By selecting for a subset of the isolated RNA, one does
not obtain a global small RNA profile of the vesicles
under study. This can be an advantage if focusing on
the analysis of a specific subset of small RNA, due to a
gain in sequencing depth and thus the possibility of
identifying low abundance RNAs, but it makes
comparisons of RNA levels across differently sized
transcripts challenging.
A third source of bias is introduced by the sequence
platform used (e.g. HiSeq or MiSeq systems from
Illumina, Ion Torrent or SOLiD system from Life
Technologies, and others) and the subsequent bioinfor-
matics analysis of obtained data. For example, it was
discussed during the workshop that the order in which
reads are mapped to multiple databases can have a
dramatic effect on results: this is particularly pertinent
for small RNAs, i.e. piRNA and tRNA. Because small
RNASeq reads are 30 bp or less in length, many reads
fall into a category of “multi-mappers”. The sequences
cannot be confidently assigned to any one RNA bio-
type, but instead could be counted in many categories
of small RNA. In general it is recommended to map to
a concatenated database if possible, or, if mapping to
multiple databases with stepwise removal of mapped
sequences, to state clearly which order was used.
Further considerations for bioinformatic analysis of
EV-RNA sequencing data are outlined in the previous
ISEV position paper on “extracellular vesicle RNA
analysis and bioinformatics”.[9] As described in that
paper, various parameters including the set-up of the
analysis pipeline and data normalisation are crucial
steps in interpreting sequencing data for EVs. Thus,
processing steps applied to the raw data such as trim-
ming/clipping of adapters, cut-off values and specific
databases used for sequence annotation should be
clearly described in publications in order to allow
comparison of studies. Sharing of pipelines and raw
data, as is often performed in genetics research, would
lead to even better reproducibility and standardisation
in the field.
It should above all be noted that none of the avail-
able methods is completely unbiased, and therefore all
libraries in a given project should be created in a
consistent manner throughout, and expression of key
transcripts validated using a second platform, e.g. RT-
qPCR. When comparing across projects from different
Table 3. Common sources of bias in RNA isolation and sequencing methods.
Source Example Solution
Size selection Underrepresentation of mid-size RNAs in RNA
sequencing experiments
Tailor size selectivity of RNA purification technique to size of RNA of
interest.
If analysing total RNA, perform multiple extractions for differently sized
populations.
Extraction reagent TRIzol induces GC content bias in small RNAs Use alternative RNA extraction reagents for comparison.
Library preparation kit
or protocol
Adaptor ligation bias Use newly developed strategies to control for ligation bias, i.e. 4N
adapter-based kits.
Sequencing platform Different biases in different sequencing platforms Use of identical platforms for experiments to be directly compared.
Corroborate important conclusions with a second technique.
Bioinformatics Mapping order Map to concatenated databases and clearly indicate order of steps if
mapping to multiple databases.
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laboratories using different sequencing kits, the data
should be examined with consideration of the differing
biases that may be present. Many problems encoun-
tered by EV-RNA researchers are familiar to practi-
tioners of single-cell RNA sequencing, given the shared
challenge of low input material, and it would thus
perhaps be prudent to keep an eye out for solutions
from the single-cell field to some of these issues.
2.4. Normalisation strategies and reference
transcripts
A number of strategies are in use for normalising EV-RNA
data, as was discussed in the previous position paper.[9]
Commonly used methods include normalisation over the
total number of mapped reads or the number of reads
mapping to a specific class of RNAs (e.g. miRNAs). During
RT-qPCR validation of EV-RNA data, it is important to
include validated reference gene transcripts, preferably
three or more.[88] Reference genes should preferably be
in the same size range as the transcript of interest. To
evaluate the best and most stable reference gene combina-
tion for expression normalisation, various mathematical
algorithms are recommended, such as Genorm,
Normfinder or “Pattern Recognition Analysis”.[88–90]
Alternatively, the geometric mean of all mRNA or
miRNA analysed in the study (geomean) has been sug-
gested to serve as an accurate normalisation factor.[88,91]
Other authors recommend a combination of various algo-
rithms to identify the perfect normalisers.[92] Reference
transcripts often used to normalise expression levels
between cellular RNA samples are not necessarily reliable
for normalising EV-RNA data. The reason for this is that
RNAs stably expressed between cells in different condi-
tions could still be differentially sorted into EVs released by
these cells. Therefore, EV-RNA reference gene candidates
should be extensively evaluated for their stable presence in
each of the different experimental conditions tested.
Various researchers rely on non-coding RNAs such as
snoRNA or U-RNA as endogenous reference genes for
normalisation,[92,93] although these RNAs differ substan-
tially in length and stability from miRNAs. Moreover,
other reports have described sno- and U-RNAs as extra-
cellular biomarkers in other contexts.[94] Justification of
the choice of particular transcripts as expression normali-
sers must be included in manuscripts, following the MIQE
guidelines.[55] During the workshop, RNA spike-ins were
discussed as a normalisation strategy, since these were
recommended in the previous EV-RNA position paper.
Synthetic miRNA spike-ins have been used for normal-
isation in several studies.[46,95,96] Addition of spike-in
RNA to EV samples during RNA extraction serves to
normalise RNA isolation efficiencies between samples.
Adding a spike-in to equal amounts of isolated RNA
does not control for technical variations in RNA quantifi-
cation, but may be used to compare PCR efficiencies
between samples.
A final factor to consider, especially when attempting
to compare relative RNA expression levels of a given
species between the cellular and EV sample, is the PCR
efficiency in different sample types. Depending on the
RNA sample composition and the levels of possible con-
taminants, the PCR efficiencies of a particular primer set
can differ considerably. In these cases, the simplified
ΔΔCt method [97] can lead to erroneous results, espe-
cially if cellular and EV-RNA amplification curves (and
corresponding Ct values) differ significantly. These issues
may be addressed by determining the PCR reaction effi-
ciencies using calibration curves or other relative quanti-
fication methods, or by conducting absolute quantitation
of studied transcripts.[98,99]
New advances in both EV isolation techniques and
RNA quantification, including careful optimisation and
standardisation of existing techniques and protocols, will
certainly foster progress towards more reliable EV-RNA
characterisation and identification of specific biomarkers.
3. Diversity in EV-RNA content and
mechanisms underlying RNA sorting into EVs
As mentioned in section 1, it is currently thought that
the RNA content of EVs likely differs according to the
parent cell type, cell status, and the subcellular location
where the EVs were formed. Although there are several
indications that sorting of RNAs into EV is a regulated
process, discussions at the EV-RNA workshop sug-
gested that the biological mechanisms underlying this
distribution of RNAs among EVs are largely unknown
and that the relative contributions of passive and active
loading of RNAs into EVs remain unclear. There is also
limited information on exactly how RNA loading var-
ies by cell activation status and pathological conditions,
due to the technical challenges in gathering this data.
As most of the common EV isolation methods are not
able to distinguish between different vesicle subpopula-
tions, and the exact subpopulations relevant to a parti-
cular disease state are not known, differential sorting of
RNA during cell activation or diseases may be difficult
to detect in heterogeneous EV mixtures.
Understanding the molecular mechanisms underlying
specific incorporation of RNAs into EVs is not only
important for understanding potential biological func-
tions, but is also an important prerequisite to rationa-
lising their use as disease biomarkers. In the following
section, we summarise recent developments in the field
of EV-RNA loading, identify the major questions
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within this topic, and provide suggestions for how to
address these questions in the near future.
3.1. What is known and what is suggested by
recent findings?
3.1.1. Intracellular versus EV-associated RNA profiles
It is now well established that the activation and differ-
entiation status of cells are reflected in EV-associated
RNA released by those cells. In cell culture, environmen-
tal stressors such as hypoxia [100–102] and oxidative
stress [103,104] alter EV-RNA profiles in a manner con-
sistent with shifts to the RNA profile inside the cell.
Modification of EV miRNA profiles have been associated
with cancers,[105–110] autoimmune diseases,[111–113]
asthma [114] and cardiovascular disease.[115] There is
growing evidence that microbial infections lead to
changes in the RNA content of host EVs, and that patho-
gens and commensals may modulate the host’s immune
system via EVs. Macrophages secrete EVs with different
RNA content after infections with e.g. HIV [116] or
Epstein-Barr virus.[117] Similar findings have been
observed for Hepatitis C,[118] Enterovirus 71,[119] and
Mycobacterium tuberculosis.[120] Of note, the isolation
of virus-free EV preparation from infected cells is chal-
lenging,[121,122] and may impact the observed diversity
of EV-associated RNA.
Although EV-RNA content can clearly reflect changes
in the RNA profile of parent cells, the extent of this
association and its applicability to all or only certain
RNA species remain open to debate. Independent studies,
for example, have reported profound differences between
intracellular RNA profiles of cell lines and EVs recovered
from these cells. Recurrent observations include an
increased relative abundance of small RNAs in EVs,
[22,123] and the prevalence of ncRNA fragments (from
e.g. vault RNA, Y RNA, and specific tRNAs) among small
RNA species.[70,72,73] Thus, observational studies sup-
port that certain RNA subtypes are preferentially detected
in EVs over others. We will return to possible explana-
tions for this in the following sections.
With regard to the specificity of miRNA inclusion in
EVs, some labs have found a strong correlation
(r > 0.9) between intracellular and extracellular
miRNA profiles,[46,73] while others found weaker cor-
relations (r = 0.5–0.7), observing that certain EV-
enriched miRNAs were common to different cell
types.[22,124] This discrepancy may be explained by
differences in experimental procedures, causing differ-
ential sensitivity for detecting low abundant RNA in
EVs or cells or biases in isolation of different EV
subpopulations and RNA-containing contaminants
(see section 2 for more discussion). For example, recent
data suggest that co-isolation of contaminating RNA
present in foetal bovine serum, generally used in cell
culture medium, may directly affect observed abun-
dances of miRNAs in EV-RNA preparations.[28]
Depicted in Figure 2 and described below are molecu-
lar players and pathways that are currently thought to
be involved in incorporation of RNAs into EVs.
3.1.2. RNA binding proteins are likely involved in EV-
RNA sorting mechanisms
As emphasised by an overview speaker at the work-
shop, RNases are ubiquitous in the cell and in the
various extracellular spaces of the body; individual
RNAs are protected from degradation chiefly through
association with RNA binding proteins (RBPs) and
their molecular interaction partners. For example,
while unprotected mature miRNA is destroyed within
seconds to minutes in biological settings (e.g. in blood
[125]), AGO-bound but inactive miRNAs can persist
for as long as several weeks.[126] Therefore, any dis-
cussion of RNA sorting is necessarily a discussion of
RNA–protein association and complexing with other
binding partners. As noted at the workshop, until now
the field has mostly focused on EV-associated miRNAs
and their association with RBPs, including those
involved in the biogenesis and function of miRNAs.
The canonical binding partners and effectors of
miRNAs are AGO proteins, four versions of which are
encoded in the human genome (AGO1–4). Mature
miRNAs are loaded into AGO during the pre-miRNA
maturation process mediated by Dicer. Once associated
with AGO, the miRNA is “committed” and cannot easily
be competed away by excess molecules.[127] This, com-
bined with the fact that an unloaded miRNA is rapidly
degraded,[128] suggests that miRNAs associated to EV
may only be functional in a recipient cell if an entire
AGO-miRNA complex is transferred. As such, it is of
interest to investigate whether the abundance and avail-
ability of AGO- or miRNA-interacting proteins like
human embryonic lethal abnormal visual (ELAV proteins
or human antigen R (HuR),[129,130] Dicer,[131] trinu-
cleotide repeat-containing gene 6 (TNRC6) proteins [132]
or fragile Xmental retardation syndrome-related protein 1
(FXR1) [133] play a role in selecting miRNAs for EV
export. There is evidence that these AGO- and other
miRNA-interacting proteins interact with endomem-
branes. MVB [134,135] and endoplasmic reticulum (ER),
[136] for example, were shown to associate with compo-
nents of the miRNA effector complex (AGO2, TNRC6A,
Dicer) andmodulate miRNA complex assembly and activ-
ity. Moreover, AGO2 and Dicer were shown to be selec-
tively degraded by the autophagosome,[137] and AGO2
directly interacts with a transmembrane form of the
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endogenous prion protein (PRNP), which allows the
assembly and stabilisation of AGO complexes on the
endolysosomal membrane network.[138] Interestingly,
while both TNRC6A and AGO2 interact with MVBs,
Gibbings et al. [134] reported that only TNRC6A was
enriched in MonoMac-derived EVs, thereby suggesting
that additional mechanisms are required for their prefer-
ential incorporation into EVs. Several studies have
reported a relative depletion or even absence of AGOs
from EVs,[32,139] while others detect significant amount
of AGOs.[76,140,141] Workshop participants discussed
various reasons for the difficulties in detecting EV-asso-
ciated AGO, and there was a consensus that it is still an
open question whether AGO is generally associated with
EVs or not. Apart from differences in the purity of EV
preparations used in these studies, the discrepant findings
may also be explained by context- or cell type-specific
regulation of AGOs on endomembranes.[140] It is also
worth noting that Squadrito et al. [142] established a
correlation between the level of “free” intracellular AGO-
miRNA complex (not associated with mRNA targets), and
their preferential enrichment in EVs. Interestingly, while in
vitro cultured proliferating cells have a majority of their
AGO-associated miRNAs engaged into a high molecular
weight complex RNA-induced silencing complex (HMC-
RISC) containing mRNAs, most cells in differentiated
RNA
sequence
(hnRNPA2B1,
YBX1, ANXA2)
RNA
structure
(HuR)
RNA
3’editing
(TUT7)
miRNA/
siRNA
(AGO2)
membrane-
bound RBPs
(ESCRT-II)
Sumoylation
Phosphorylation
Ubiquitination
Su
P
Figure 2. Suggestedmechanisms for EV-RNA sorting by RNA-binding proteins (RBPs). RNAmay be packaged into EVs via active or passive
mechanisms. RNA-binding proteins (RBPs) could bind intracellular RNAs bearing certain motifs or signals (structure, sequence or size) (1).
Specific interaction between RNA/RBPs and endomembranes through docking receptors (2) or microtubule-docking receptors (3) may
result in the local enrichment of RNA close to membrane compartments, thereby modulating their selective incorporation into EVs (4 and
5). Alternatively, RBPs may also be passively incorporated into EVs and protect their cargo in the extracellular space (6). Non-templated
RNA modifications (e.g. uridylation) known to regulate RNA-turnover in cells (7), are also hypothesised to impact EV-RNA sorting by a still
unknown mechanism. Upon viral infection, cellular stress, or miRNA-induced silencing, RNA can be selectively stored in cytoplasmic RNA
granules (e.g. P/GW bodies) (8). This may balance their passive/active incorporation into EVs, either negatively by decreasing their soluble
pool, or positively by interactions between GW-bodies and MVBs (9). The depicted processes may be tightly regulated by distinct
signalling pathways (e.g. RAS, AKT) that trigger specific post-translational modification (PTMs) on RBPs or RNA-editing on transcripts,
thereby affecting the stability and subcellular localisation of RNA/RBP complexes (10).
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mammalian tissues express AGO-miRNA as a “free” low-
molecular weight complex (LMC-RISC).[143] Moreover,
cell stimulation (e.g. T-cell activation), could induce the
mobilisation of AGOs from its LMC- toward the HMC-
pool.[143] Moreover, alteration in cell signalling (e.g.
oncogenic RAS) was shown to alter the pool of P-body-
vs. MVB-associated AGO2, by modulating AGO phos-
phorylation.[140] Altogether, these observations suggest
that AGO2 post-translational modifications and the mod-
ulation of the level of endogenous miRNAs targets, may
directly modulate the export of AGO2-loaded miRNAs
into EVs,[144,145] either by promoting the association of
AGO2 to MVBs, or by modulating the pool of AGO2 that
could be passively or actively engulfed into EVs.
Beyond AGOs and their direct partners, other proteins
have been proposed to directly affect miRNA sorting.
hnRNPA2B1 has been suggested to regulate EV sorting
of miRNAs containing a specific motif [146] when mod-
ified by a small ubiquitin-like modifier, SUMO, which in
mono-attachment does not target proteins for degrada-
tion, but instead regulates stability and subcellular localisa-
tion.[147,148] Interestingly, constitutive activation of
mutated forms of KRAS, frequent in certain cancers, was
recently shown to promote EV-associated release of spe-
cific miRNAs, while inducing intracellular retention of
others.[149] Downregulation of Annexin A2 (ANXA2), a
protein exhibiting Ca2+-dependent phospholipid-binding
protein and RNA-binding properties,[150] was shown to
decrease the level of EV-associated miRNAs, without sig-
nificantly impacting the abundance of released EVs.[151]
In addition, HuR protein, an ELAV RBP family protein,
blocks particularmiRNAbinding sites on target transcripts
[152] and facilitates RISC dissociation from target mRNA.
[153] The first author of the latter study reported at the
workshop and now in publication [129] that in stressed
hepatic cells, HuR also binds miR-122 after dissociating it
from AGO2, and would promote its release at the surface
of the MVB to favour its incorporation into EVs. A similar
mechanism involving the RNA-binding protein Y-box
protein 1, a known EV-associated protein,[154–157] was
recently identified by Shurtleff et al. [139] using cell-free
assays for exosome biogenesis. It was shown that YBX1
binds to specific miRNAs (e.g. miR-223) and promotes
their selective packaging into CD63+ EVs. Interestingly,
knocking out YBX1, alone or in combination with addi-
tional knockdown of its homologue YBX2, led to a strong
depletion of YBX1-bound siRNA into EVs, and their
remobilisation into cellular AGO2. Future work should
address whether miRNA dissociation from AGO and sub-
sequent binding by non-AGO RNA-binding proteins
(such as hnRNPA2B1, Annexin A2, HuR and YBX1) is a
general phenomenon that may contribute to EV-RNA
sorting. Moreover, as these RBPs are known to bind to
other type of RNAs (including mRNA, tRNA and
snoRNAs) it will be important to decipher whether they
could also promote the packaging of these RNA biotypes
into EVs.
Finally, proteins implicated in EV biogenesis can
influence RNA loading into EV. Modulation of endo-
somal sorting complex required for transport (ESCRT)
activity can impact both the number of released EV
and EV-RNA abundance. For example, Vps4 was
found to influence the secretion of oncogenic
miRNAs by human hepatoma cells.[158] Interestingly,
knocking down Alix, another ESCRT protein, did not
affect the number of released EVs but induced a
decrease of secreted miRNAs.[159] It should be noted
that ESCRT complex is also involved in the regulation
of the RNA silencing pathway,[134] thereby complicat-
ing the interpretation of these observations.
3.1.3. RNA motifs and modifications associated with
EV incorporation
As intimated above, several RNA motifs have been
identified that correlate positively with release in EVs.
A GGAG motif in miRNAs, recognised by
hnRNPA2B1, has been suggested to promote packaging
into EVs.[146] Studies involving analysis of transcripts
enriched in EVs over their secreting cells have also
identified motifs that positively correlate with RNA
targeting to EVs.[160,161]
Besides the recognition of specific RNA secretion
motifs, the addition of non-templated nucleotides has
been reported to determine RNA fate; 3′ adenylation of
miRNAs has been associated with intracellular reten-
tion whereas uridylated isoforms are more enriched in
the small vesicles fraction.[84] This could suggest that
the 3′ end of the miRNA sequence contains a critical
signal for sorting into EVs, or that the specific subcel-
lular localisation of RNA-editing enzymes directly
impacts this sorting. Alternatively, the 3′ uridylation
may indicate the presence of apoptotic bodies in the
EV isolate, since this is also a signature of RNA under-
going degradation during apoptosis.[162] The possibi-
lity of mutating the packaging motif of specific EV-
associated RNA (using CRISPR-mediated homologous
recombination) or mutation/overexpression of key
RNA editing enzymes (e.g. TUT7) may allow this ques-
tion to be addressed.
In conclusion, as typified by strong recent work on
miRNA, EV-RNA sorting mechanisms are likely to
involve RNA binding proteins and their partners,
although other mechanisms may exist (Figure 2). The
focus on miRNAs at the workshop and in this article is
simply a reflection of the field; indeed, diverse other
classes of cellular RNAs, or their fragments, have been
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reported in EVs.[70] Below, we specify potential
research directions to uncover how these diverse RNA
species are packaged into EVs.
3.2. Remaining questions and how we can answer
them
3.2.1. How can the varying correlations between
cellular and EV-associated RNA contents be
explained?
As previously mentioned for the case of miRNAs,
different studies report differing degrees of correlation
between intracellular and EV-RNA content.
[22,46,73,124,163] At the most basic level, all EV-
RNAs originate in cells, and thus any EV-RNAs must
also exist at least transiently in the parent cell. We can
readily envision four distinct but non-exclusive scenar-
ios that might contribute to observed relationships
between cellular and EV-associated RNA:
(1) Cellular RNAs are randomly included in the vesicle
lumen during EV biogenesis, yielding an EV-RNA
profile representative of the relative RNA abun-
dance at close proximity of the EV luminal engulf-
ment site. Note that this scenario does not
necessarily mean that EV and cellular RNA would
correlate perfectly. Also, random RNA packaging
might be limited by the length of prospective pack-
aged RNAs and the size of RNPs. In a pure example
of this case, the EV-RNA profile would be roughly
identical to that of cellular membrane-associated
RNAs;[164] for example, those near MVBs, or
endosome-like domains of the plasma membrane.
The recent development of a high throughput
method to determine subcellular localisation of
RNA in situ [165] may facilitate the identification
of such bias in the future.
(2) Cellular RNAs are included in the vesicle lumen
based on their proximity to the site of engulfment,
but with enrichment provided by affinity of RNA
motifs and/or RNP components for protein and
lipid elements preferentially found at sites of EV
biogenesis.[139] Here, EV-RNAs would approxi-
mate a subset of membrane-associated RNAs,
enriched in a particular sequence or protein
association.
(3) RNAs harbouring specific structural or sequence
signals are loaded into EVs in an energy-depen-
dent, i.e. active, manner. Interestingly, some
RNAs might “bring their own” ATP, as ATP-
binding motifs have been identified.[166]
Depleting ATP from parent cells would presum-
ably be an experimental approach to identify
active loading processes, although careful con-
trols would be necessary. However, workshop
participants were unaware of any reported
ATP dependence in EV-RNA sorting pathways.
(4) Finally, it remains a possibility that recycling
mechanisms operating in cells (e.g. RNautophagy)
would lead to continuous EV incorporation of a
large range of cellular RNAs at a given time.
[167,168]
As discussed, it is anticipated that more than one of the
above are likely to define the relationship of cellular and
EV-RNA, complicating the picture substantially.
Resolving the relative contributions of different scenarios
in different contexts is an area of much-needed research.
3.2.2. Can further research into RBPs and their
partners lead to discovery of mechanisms underlying
RNA sorting into EVs?
It may be informative to explore the roles and interaction
partners of RBPs that are already known to be present in
EVs, as these may be involved in the stabilisation and/or
sorting of EV-RNA. As an example of this approach, a list
of known curated RBPs [169] could be compiled based on
overrepresentation in databases that compile EV proteo-
mics data, such as Vesiclepedia,[170] Exocarta [171] and
Evpedia.[172] In a preliminary exercise using Vesiclepedia
(see Table 4), we note that, apart from enrichment for
general translation machinery factors, EVs contain tRNA
associated factors (EEF1A1, AARS, GARS, DARS, TARS,
WARS) and more specialised RBPs such as CNP, PARK7,
RNH1, RUVBL1/2, HNRP-K/A2B1/C/D/R, PCBP1,
DHX9, NPM1, PARP1, SND1, SYNCRIP, and MVP
(major vault protein). Future investigation will be required
to validate these observations, and notably to exclude
possible contamination of EV preparation with co-fractio-
nating RBPs. It should also be emphasised that there are
caveats to this approach. For low abundance EV-RNAs,
RBPs with one-to-one binding stoichiometry might be
difficult to detect in EVs. Furthermore, shuttling proteins
may exist that transfer RNAs from cellular to EV binding
partners while remaining themselves excluded from EVs.
3.2.3. Which EV-associated RNAs are inside vs.
outside EVs?
In addition to the question of whether specific RNAs are
destined for release via EVs, it is also unclear in a given
preparation whether EV-RNAs localise both in the EV
lumen and on the outside of the EV membrane. Though
the possibility of a functional association of RNA with the
outside of the EVmembrane cannot be formally ruled out,
no evidence for it has been observed, and this topology
would be inconsistent with the traditional model of RNA
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delivery by vesicle fusion with the recipient cell. In addi-
tion, observed outside associations with RNPs may be
technically induced by isolation procedures (i.e. force of
centrifugation) rather than biological in nature. RNase
treatment of EVs has been applied to deplete non-encap-
sulated RNA;[27,73] however, even RNAs exterior to EVs
are likely to be protected from RNase degradation by
protein complexes, as there are already high levels of
RNase in biological media such as blood plasma.[26] To
selectively study RNA residing in the vesicle lumen, it is
critical to eliminate any source of RNA outside the vesicles.
We therefore recommend that investigators quantify the
amount of EV-associated RNAs (for example by RT-
qPCR) before and after treatment of the vesicle with a
proteinase followed by an RNase digestion step. By com-
bining this approach with a negative control (proteinase/
RNase digestion in the presence of detergent, as in Royo
et al. [173]), it is possible to determine the proportion of a
specific RNA residing within the vesicle in a given
preparation.
3.2.4. Does subcellular localisation affect sorting
into EVs?
It has been hypothesised that the subcellular distribution of
RNAs can promote the inclusion of particularmolecules in
EVs. Similarly, the location of RNA species in the different
compartments – i.e. cytoplasm, nucleus or plasma mem-
brane – could determine their in/exclusion in different
types of EVs (large microvesicles, apoptotic bodies, or
exosomes). Increased knowledge on sub-cellular localisa-
tion of different RNA species is needed to further address
this issue. In general terms, crucial decisions onmaturation
of both mRNAs and ncRNAs (i.e. splicing, polyadenyla-
tion) are made during their time in the nucleus, suggesting
that the nuclear history of an RNA can be fundamental for
its fate in the cytoplasm. Once in the cytoplasm, RNP
complexes containing mRNAs and/or other ncRNAs
interact with motor proteins, which mediate their traffick-
ing, mostly in inactive form, along the cytoskeleton tracks
to their final destinations.[174] It is possible that the same
mechanisms active in RNA pre-localisation also function
in specific sorting of RNP to nascent EVs. Notably, in the
nervous system, intracellular RNP trafficking seems to be
regulated by neurotransmission (reviewed in [175]) and
the same has been also reported for EV trafficking among
different brain cell types (reviewed in [176]). It is likely that
the mechanisms governing subcellular RNA localisation
are important for their specific packaging into EVs. Future
experiments characterising these processes will be key to
validating this hypothesis. For example, detecting changes
in subcellular RNA localisation by fluorescent in situ hybri-
disation (FISH) [177] or using indirect RNA-binding pro-
tein detection (e.g. with the MS2 system) [178] could
provide insight on the relevance of localisation within the
cell for the packaging of a given RNA transcript.
3.2.5. Differential stability of RNA in EVs?
It has also been proposed that differences in EV-RNA
profiles versus intracellular RNA profiles are not the
result of a selective process, but rather represent dif-
ferences in the extracellular stability of particular
RNA species.[179] Certain RNases may be present at
higher concentration in EVs than in the cell, inducing
the relative depletion of RNAs targeted by these
RNases in EVs.[180] Moreover, the portion of RNAs
bound by RBPs inside EV might be preferentially
stabilised and resistant to RNases. This may be
addressed by searching for known RBP binding motifs
specifically enriched in RNA isolated from EV com-
pared to the parent cells.
Table 4. Top 80 RNA-binding proteins in Vesiclepedia datasets.
Poly-A RNA-binding
Vault complex 
MVP
RPS8 RPS5 RPL4
RPS16 RPS24 RPL7
RPS18 RPS6 NCL
RPS27A RPL15 RPS9
RPLP0 RPS3A RPL6
RPSA RPL18 RPL27
RPS3 RPS13 RPS7
RPS4X RPL30 RPS11
RPL12 RPL3 RPL19
RPS14 RPS25 RPL13
RPLP2 RPS2 RPL23
RPL7A RPS15A
ribosome function
EEF2
EIF4A1
EEF1G
EEF1A2
EIF5A
EEF1D
EIF2S1
EEF1A1
AARS
GARS
DARS
TARS
WARS
GAPDH IPO5
PRDX1 ACO1
UBA1 CANX
RAN XRCC6
PSMA6 CRYZ
KPNB1
PSMA1
DYNC1H1
CALR
CNP DHX9
PARK7 HNRNPA2B1
RNH1 HNRNPC
RUVBL2 PA2G4
HNRNPK HNRNPD
RUVBL1 NPM1
PCBP1 SND1
PARP1
SYNCRIP
HNRNPR
tRNA functiontranslation unclear RNA-binding
Top 80 RNA-binding proteins in Vesiclepedia datasets. The occurrence of each protein within a census of 1542 manually
curated RBPs [169] was queried within the Vesiclepedia database (http://www.microvesicles.org; v3.1; restricted to Homo
sapiens samples). Proteins are clustered by functional group with colours indicating the number of occurrences in the
database (30–39 blue; 40–49 orange; >50 red).
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3.2.6. Do RNA modifications impact their sorting
into EVs?
Accumulating evidence indicates that an array of RNA
modifications (5′-end cap, m6A: N6-methyladenosine,
m5C: 5-methyl cytidine, A-to-I editing, pseudo-uridine,
5hmC: 5-hydroxylmethyl cytidine) directly control RNA
metabolism (reviewed in [181]). These RNAmodifications
are tightly controlled by cellular enzymes (e.g. m6A “wri-
ters” METTL3, m6A “eraser” FTO), and could be recog-
nised by RNA-modification “readers” (such as YTHDF1)
that could impact the stability [182] of modified RNA. As
for the addition of non-templated nucleotides to the 3′ end
of the RNA (adenine, uridine, see also section 3.1.3), an
interesting hypothesis would be that these modifications
may favour specific packaging of these RNAs into EV.
Novel techniques have recently been developed to detect
specific RNA modification (e.g. MeRIP-seq [183]).
Applying these approaches to EV-associated-RNAs
would enable analysis of whether RNA modifications are
enriched or depleted in EV-associated RNA.
3.3. Next challenge: qualitative and quantitative
RNA analysis in individual EVs
Since EV populations can be highly heterogeneous, a full
understanding of RNA incorporation into EVs will
require analysis at the EV subpopulation or individual
EV level rather than bulk analysis. However, detecting
and enumerating RNA molecules in individual EVs face
unmet challenges. As technologies for analysis and isola-
tion of individual EVs are rapidly improving,[19,184–
187] the opportunities to investigate the EV-RNA cargo
of single EVs are expanding. Attempts have been made to
apply fluorescent RNA-tracking dyes (e.g. acridine
orange, Syto84 or Syto-RNASelect) for high-resolution
flow cytometric analysis of the RNA content of individual
EVs. However, the use of such an approach remains
challenging due to limited probe specificity, limited fluor-
escence per EV, and poor signal-to-background ratio. For
example, fluorescent small molecules that are highly spe-
cific for RNA tend to be charged and thus membrane
impermeable, hampering labelling of RNA in the EV
lumen. Table 5 lists several membrane-permeant fluor-
escent dyes that may be used to detect the presence of
RNA associated with EVs, although their specificity and
efficiency in labelling EV-RNA remain to be validated.
It is important to mention that none of the cur-
rently utilised single EV analysis cytometry-based
methods are capable of detecting a single fluorescein
molecule. When using molecular equivalents of solu-
ble fluorescein (MESF) calibration, it has been
demonstrated that hundreds or thousands of fluores-
cein equivalents are commonly required for detection,
depending on the instrument and configuration
(ISEV-ISAC-ISTH working group, ISEV 2016).
Moreover, most RNA dyes are intercalating agents
and it is not expected that the structure of a small
miRNA would support intercalation of hundreds of
dye molecules. Labels with higher quantum yield (and
better signal:noise ratio), such as quantum nanocrys-
tal-labelled oligonucleotides, may be more suitable for
detection of molecular components in single EVs. In
addition to flow cytometry, Raman spectroscopy was
recently used to analyse single EVs in solution, allow-
ing distinction of several distinct EVs populations
differing in chemical properties.[195,196] However,
it is currently unclear whether this technique may
allow detection of RNA in single EVs.
Innovative methods were recently developed to indir-
ectly detect RNA in EV by microscopy, notably by using
RNA-binding fluorescent protein probes. One multi-
plexed approach [197] combines the labelling of vesicle
membranes using a palmitoylated fluorescent protein,
and the indirect labelling of RNA molecules using the
bacteriophage MS2 coat protein-GFP:MS2 RNA binding
sequence system.[178] Although this method may be
restricted to the labelling of long RNA (e.g. lcnRNA or
mRNA) and the target RNAmust be modified to include
the MS2 loop, it is a promising strategy to monitor the
packaging of extracellular RNAs into EVs in living cells. It
would be interesting to further develop this approach to
investigate the percentage of RNA-loaded EVs or to
Table 5. Membrane-permeant fluorescent dyes that may be used to detect the presence of RNA associated with EVs.
Dye Ex/Em (nm) Known nucleic acid specificity
Publication for cell
staining
Publication EV
staining
Acridine orange (Thermo Fisher Scientific) 460⁄650 (RNA)
500⁄526 (DNA)
dsDNA (Green) and ssDNA/dsRNA
(Red)
(orange emission in acidic organelle
compartments)
[188] [189]
Pyronin Y (Sigma, Saint Louis, MO, USA) 555/580 ssRNA [190] No
Syto14 (Thermo Fisher Scientific) 517⁄549 (DNA),
521⁄547 (RNA)
RNA/DNA [191] No
SYTO-RNASelect (Thermo Fisher Scientific) 490/530 RNA selective [192] [193]
E36 497/548 RNA selective [192] No
Styryl-TO 520/531 RNA selective [194] No
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combine with the use of fluorescent-tagged markers of
sub-cellular compartments in order to infer the endo-
membrane origin of EVs containing RNA.
During the workshop, participants suggested applying
digital droplet PCR methods to quantify the RNA content
in single EVs, although it is not currently clear whether this
methodology will be applicable to single vesicle analysis.
Another approach would be to perform PCR on limiting
dilutions of EV preparations, so that each PCR is initiated
from the RNA content of a single vesicle. A microfluidic
PCR platform would likely be necessary to analyse such a
small amount of RNA. Finally, it would be interesting to be
able to “visualise” specific RNA within the vesicular con-
text. Protocols developed to detect RNA within virus par-
ticles by RNA FISH [198] or in situ hybridisation-electron
microscopy (ISH-EM) [199] could likely be applied to
detect EV-associated RNA given their comparable size
and chemical nature. In fact, the high resolution of the
ISH-EM method may allow determination of whether
specific EV-RNA are located inside or at the surface of
vesicles, a point remaining controversial in the field.
4. Assessing functional transfer of EV-RNA
In the past 10 years, EVs were not only shown to contain
RNA, but also to be able to functionally transfer RNA into
target cells. It is important that this process is studied using
different experimental models and by mimicking physio-
logical EV(-RNA) concentrations and conditions, both in
vitro and in vivo. The formal demonstration that EV-
mediated effects on target cell behaviour are caused by
functional transfer of EV-RNA is technically challenging
and requires a number of important controls in order to
validate observations. Below, we describe the current
approaches used to investigate EV-RNA transfer and dis-
cuss advantages and pitfalls of these methods. During the
workshop, there were also fruitful discussions about the
implementation of novel models/approaches in the field,
of which the most promising are also reported in the
sections below.
4.1. Strategies to study functional transfer of EV-
associated mRNA and miRNA in vitro
The first observation that mRNA could be transferred via a
pelletable fraction of cell conditioned medium and trans-
lated in target cells wasmade by Ratajczak et al. [200]. Soon
after, Valadi et al. [201] reported that RNA was indeed
associated to low-density EV, and further demonstrated
RNase-resistance of this RNA. In this study, mousemRNA
transferred via EVs to recipient human mast cells could be
translated into corresponding mouse proteins in vitro.
[201] Skog et al. [202] provided a confirmatory study
showing that, upon EV-mediated transfer, Gaussia lucifer-
ase mRNA was translated within recipient cells. Gaussia
luciferase (Gluc) is a flash-type reporter which emits a
bioluminescent signal 100-fold higher than typical luci-
ferases such as firefly or Renilla luciferases,[203] thereby
enabling detection of minute biological events such as EV-
RNA translation. Later on, Pegtel et al. [117] showed that
viral miRNAs secreted by EBV-infected cells were trans-
ferred to uninfected recipient cells via EVs and could
repress the EBV target genes using a luciferase sensor
assay. Shortly after, Kosaka et al. [204] and Zhang et al.
[141] documented functional cell-to-cell miRNA transfers
in destination cells using EVs isolated from miRNA-over-
expressing cells, by using a luciferase sensor assay,[204] or
by showing direct repression of endogenous miRNA tar-
gets at the protein level.[141] Another method to investi-
gate spatial and temporal aspects of EV uptake and EV-
mRNA translation is via the use of bioluminescent repor-
ters. More recently, it was demonstrated that EV-mRNA
encoding a membrane-bound Gluc reporter (GlucB) can
be translated in as soon as 30minutes following EV uptake
by recipient cells.[197] While the GlucB signal began to
increase substantially from 30 min, it reached a plateau at
12 h post-EV uptake, perhaps suggesting that there is a
limit to the amount of mRNA which EVs can transfer.
4.1.1. Considerations for assessing functional
transfer of EV-associated miRNAs
A plethora of studies have confirmed the initial obser-
vations, strengthening the idea that functional transfer
of EV-associated mRNAs and miRNAs can occur in
vitro between mammalian cells. In several studies, EVs
from cells overexpressing endogenous miRNAs were
shown to cause target mRNA repression in recipient
cells transfected with a luciferase reporter construct
using the 3′UTR of the mRNA target (examples include
[22,205,206]). Besides effects on miRNA reporter sys-
tems, EV-mediated transfer of miRNA was also shown
to cause changes in target gene expression in recipient
cells.[205,207,208] These experiments are generally
performed with donor cells expressing miRNAs for
which the expression levels in the recipient cell are
very low or undetectable in order to maximise the
window in which miRNA transfer can be observed. In
order to exclude the possibility that the EVs/co-culture
treatment itself would induce the endogenous tran-
scription of the tested miRNA in destination cells,
which is a potential confounding effect in this assay,
some studies tested the level of miRNAs precursors
(pri-miRNA and/or pre-miRNA) in destination cells.
[209,210] Although the lack of changes in miRNA
precursor level would strengthen the EV-mediated
transfer hypothesis, it should be noted that: (1) pre-
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miRNAs can also be transferred by EVs;[76,211] and
(2) because the pre-/pri-miRNA are continuously pro-
cessed into mature miRNA by the RNA silencing
machinery, a transient increase in pre-/pri-miRNA
levels caused by EV treatment may easily be overseen
at a later time point, while mature miRNA may stably
accumulate for hours/days.[212,213] Therefore, detect-
ing changes in precursor miRNAs in destination cells
may not be a reliable method to control for spurious
miRNA transcriptional activation caused by EV treat-
ment or in co-cultures. In other studies, the contribu-
tion of specific miRNAs in EV-induced effects has been
investigated by blocking the function of the candidate
miRNA in donor cells using antimiRs [109,214,215] or
by using miRNA genomic knockout donor and recipi-
ent cells.[208] Since knockdown of miRNAs may lead
to changes in the phenotype and/or function of cells, it
is important to address whether the observed changes
in the function of EVs released by these cells are only
due to the lack of this particular miRNA or whether
changes in other functional molecular components
contributed to these effects. Moreover, when using
anti-miRs it is essential to use adequate controls such
as a control anti-miR that targets an unrelated miRNA
expressed at a similar level.
4.1.2. Stoichiometry of miRNAs associated with EVs
Since a population of EVs can contain many different
miRNAs, they may suppress functionally related genes
in parallel, leading to effective paracrine control over
neighbouring cells. Nonetheless, a quantitative assess-
ment of the miRNA content of EVs by a stoichiometric
approach found the miRNA/vesicle ratio in a blood
sample to be lower than 1, even for the most abundant
miRNAs, meaning that there are vesicles that do not
contain a copy of a given miRNA.[25] Based on these
observations, the notion was put forward that indivi-
dual EVs were unlikely to be functionally important
vehicles for miRNA-based communication. However,
the workshop attendants felt that there was a need for a
more nuanced consideration of these data. First, the
stoichiometry assessment relies on careful quantifica-
tion of EVs, for which there are no gold standards and
which heavily depends on EV purity and the experi-
mental approach. In addition, this study assessed only
small EVs (50–200 nm), while larger vesicles, such as
microvesicles and oncosomes, also contain miRNAs as
well as longer molecules of RNA that can contribute to
EV-RNA mediated communication. With regard to
EV-miRNA function, it may well be that EV uptake is
an infrequent but very selective event, in which rare
EVs carrying many copies of a given miRNA may lead
to miRNA-mediated silencing of mRNAs in specific
target cells. It is also possible that, by taking up multi-
ple EVs carrying a low concentration of miRNA, suffi-
cient quantities of transferred miRNA are reached to
modify mRNA levels in target cells. This hypothesis is
consistent with the observation that different miRNAs
often operate in concert to simultaneously control dif-
ferent players in the same signalling pathway. Finally,
as was also suggested by Chevillet et al. [25], very low
quantities of miRNAs may be compatible with non-
conventional functions, such as binding to Toll-like
receptors as well as affecting DNA transcription and/
or epigenetic states.[216–219] More complete knowl-
edge of EV heterogeneity, target cell specificity, and
RNA transfer efficiency is therefore needed to further
address issues of EV-RNA stoichiometry.
4.2. Assessing functional EV-RNA transfer in vivo
It currently remains to be determined whether functional
transfer of EV-RNA occurs and is relevant in vivo during
physiological or pathological processes. EV-RNA transfer
assays in the context of cancer cell xenografting or
immune cell function are among the currently used
experimental set-ups in vivo.[220,221] In these studies,
effects of EVs in vivowere assessed by in vitro isolation of
EVs followed by their re-introduction in vivo. However,
this approach is unlikely to reflect the physiological prop-
erties, concentration, and distribution of EVs released in
(patho)physiological conditions. Recently, other
approaches have been introduced to more directly
address whether EV-RNA functional transfer occurs in
vivo. During the workshop, the most intensively dis-
cussed in vivo approach was the Cre-loxP-based EV tra-
cing system to study functional transfer of mRNA.
Possibilities and limitations of this approach are
described in the following sections.
4.2.1. Assessing EV-associated mRNA translation
using the Cre-loxP system
The Cre-LoxP system is a recombination system, origi-
nating in the bacteriophage P1, consisting of the DNA
recombinase Cre, and the recognition sequence loxP.
Sequences that are flanked by loxP sites will be excised
by Cre and re-joined leaving a single loxP site. EV-
mediated transfer and translation of the Cre mRNA in
target cells can be visualised by using donor cells expres-
sing Cre recombinase and recipient cells containing a
Cre-inducible open reading frame coding for a fluores-
cent protein, e.g. with a stop signal terminating transcrip-
tion that is flanked by LoxP sites. If functional Cre mRNA
is transferred by EVs to the recipient cells, the “transcrip-
tion block” impairing fluorescent protein (FP)
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transcription is genomically eliminated leading to the
irreversible production of the FP in the recipient cell.
Using this Cre-loxP system, functional transfer of EV-
RNA between distant cells has been demonstrated between
blood and brain,[220] as well as other non-haematopoietic
organs as a proof of principle. Later, these findings were
extended to EV signalling between tumour cells and
healthy cells as well as among tumour cells.[221,222] In
both studies, Cre protein levels in EVwere below detection
levels on Western blots, suggesting that recombination
observed in target cells was caused predominantly by
EV-mediated transfer of mRNA encoding the Cre protein
(see also below). The major advantages of this approach
are its high sensitivity (a single transferred CremRNAmay
lead to the permanent transcription of a marker protein),
and its ability to detect transfer events in living cells both in
vitro and in vivo. Other important advantages implicit to
this system are knowledge of the specific cell type (i.e. Cre
expressing cells) from which EVs originate and the ability
to monitor changes in phenotype and molecular composi-
tion induced by EVs down to the level of an individual
target cell. In the following paragraphs wewill discuss what
we currently know about the system and outline both
future directions and limitations.
4.2.2. Interpretation of Cre-loxP based tracing data
Recombined cells observed after EV uptake using the Cre-
LoxP system almost certainly only represent a subpopula-
tion of cells that interact with EVs, given that EVs can exert
biological effects on their target cells that are independent
of full translation of transferred RNA, e.g. via binding of
membrane bound molecules or the transfer of protein or
lipids.[57,223–225] It was discussed during the meeting
that addition of fluorescent (lipid) dye labelled EVs to
target cells in vitro generally leads to a much higher per-
centage of target cells positive for the fluorescent dye
compared to the number of target cells that start to express
fluorescent marker proteins due to recombination upon
uptake of Cre-containing EVs. It is not clear whether cells
expressing amarker gene after Cre-induced recombination
therefore represent only a subset of EV-targeted cells, or
perhaps whether the higher labelling rates observed with in
vitro fluorescence experiments are artefactual (e.g. due to
incorporation of dye aggregates).
Additionally, researchers present at themeeting had not
found a correlation between the proximity of donor cells
and the frequency of loxP-recombination events. This last
observation may suggest that cell-to-cell transfer of EV-
RNA is likely to be systemic and involves EVs without the
need for direct cell-to-cell contact. However, within the
tumour context, the local release of EV by Cre-positive
cells and their subsequentmigration away from the recom-
bined acceptor cells cannot be excluded.
The fact that recombined cells in multiple experimental
settings display clearly separated populations with differ-
ences in their miRNA profile, phenotypic markers or
cellular behaviour compared to their non-recombined
counterparts of the same or similar lineage,[221,222] sug-
gests that the number of non-recombined false positives
cannot be very high. However, this does not exclude that
non-recombined target cells were modulated by (other)
EV subpopulations that did not confer Cre mRNA-
mediated recombination. Another important question is
whether uptake and processing of Cre mRNA-containing
EVs merely reflects the current physiological state of the
recipient, i.e. that the EV-targeted cell is already distinct
from other cells, in contrast to the notion that EV uptake
actively changes the status of the cell. At least for the case of
the induction of an immunosuppressive phenotype of
myeloid derived suppressor cells (MDSCs), experimental
evidence supports the latter: EV uptake actively changes
MDSCs to become more immunosuppressive [226,227]
although the mechanisms responsible for inducing this
change are unknown.
4.2.3. Limitations of Cre-loxP based tracing of EVs
Although elegant, the Cre recombinase based EV tracking
technique has its limitations. First, it is not quantitative for
the number of EVs transferred, as it uses a permanent
genetic switch. In addition, it is not possible to distinguish
the type of EVs mediating the transfer. As discussed pre-
viously,[221] loading of Cre mRNA in subpopulations of
vesicles might be very much cell type dependent. In EVs
that were isolated from peripheral blood serum and then
fractionated according to sucrose density ultracentrifuga-
tion, Cre mRNA could be detected in several density
fractions.[222] Sorting of Cre mRNAmay occur preferen-
tially into specific EV subpopulations, but this is difficult to
assess given the lack of standardisation of vesicle numbers
in the different subfractions and the fact that themethod of
detection of Cre (by PCR or even nested-primer PCR) is
considerably more sensitive than the ability to physically
separate EV subtypes by density gradients. It is also impor-
tant to address whether the relatively low frequency (0.2–
3%) of observed recombination events are representative
of the real frequency of EV transfer in vivo or whether they
represent a low sensitivity of this technique.
Using the Cre-loxP system, it is also imperative to con-
sider alternative explanations to EV-mediated transfer of
Cre. In a chimeric system where Cre and Cre reporter
expression occurs in physically separate cell population
such as between tumour cells, Cre mRNA or protein
could also be transferred via cellular membrane protru-
sions, such as tunnelling nanotubes (for a review see [228]).
Also, it should be mentioned that while in some studies
using Cre-loxP for testing EV-RNA functional transfer the
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Cre protein could not be detected in EVs,[220,221] others
found Cre protein in EVs after overexpression in donor
cells.[57] Although Cre is a nuclear protein not expected to
be abundant in EVs, involvement of mRNA vs. protein
must be verified. Cell fusion is another process that would
give similar observations, although in chimeric systems it
can be controlled for relatively easily by co-expressing Cre
with a marker gene (e.g. fluorescent protein). Transgenic
systems where Cre is expressed under a cell type-specific
promoter in the same cells that carry the Cre reporter
require careful assessment to exclude that observed recom-
bination events are due to a leaky expression of the pro-
moter, rather than transfer of Cre from one cell to the
other. A precise characterisation of promoter activity
extending to all tissues is rarely available and might not
apply to certain pathologies that are used. On the other
hand, some cases of apparent “misexpression” ofCremight
instead be the result of a horizontal transfer of Cre. As a
minimal requirement for this type of experiments we pro-
pose that evidence is provided that the cells in question
release Cre mRNA and/or Cre protein containing EVs and
that these EVs are sufficient to induce recombination in
target cells. The use of distinct Cre models, each allowing
Cre expression in specific donor cells, may help in ruling
out unspecific Cre expression. In addition, the use of chi-
meric mice where Cre-donor cells are grafted into loxP-
reporter mice (or the reciprocal experimental set-up where
loxP-acceptor cells are grafted into Cre-expressing mice)
can avoid the possibility of spurious expression of genomi-
cally encoded Cre in acceptor cells.
In summary, the Cre-loxP system has been and will be
a valuable tool for uncovering EV-based communication
between cells and tissues in a (patho)physiological setting.
While it requires careful implementation to address spe-
cific questions in EV biology, it is relatively easy to use
and benefits from the availability of a large number of
cellular and animal models.
4.3. Expanding and refining our experimentalmodels
During the EV-RNAworkshop, there was a consensus that
we should not restrict the functional analysis of EV-RNA
transfer to one particular type of EV. Physical properties
like size and surface chemistries of different types of EVs
may impact their capacity to functionally transfer RNA.
Although most studies perform EV-RNA transfer assays
using EVs collected from in vitro cell cultures, it would also
be interesting to investigate EV directly extracted from
their natural environment, e.g. those isolated from body
fluids and tissues. These EV may differ in surface charac-
teristics, possibly due to binding of lipid or protein moi-
eties present in tissues or body fluids to the EVmembrane.
This may influence functional RNA transfer in destination
cells, e.g. due to changes in EV binding to docking proteins
or in the delivery of EV cargo through endosomal escape
or direct membrane fusion. Isolation of EV from tissues is
technically challenging. Mild tissue dissociating reagent
(e.g. liberase) without mechanical disruption could per-
haps be used to isolate EVs from tissues without co-isolat-
ing intracellular vesicles released by broken cells. However,
it is important to keep in mind that such protease treat-
ments may affect the proteins displayed on the surface of
EVs, potentially affecting their ability to dock on or fuse
with recipient cells. Alternatively, EVmay be isolated from
in vitro maintained tissues. Another interesting approach
would be to use novel technology combining both micro-
fluidics, which facilitate concentration of the EVs in the
microenvironment, and organoid cultures, which have
been highly recommended to mimic in vivo cellular orga-
nisation.[229] Indeed, 2D-grown cellsmay not recapitulate
certain features required for proper release or reception of
functional EV-RNA (e.g. cellular polarisation [230]).
Knowledge acquired in this area could ultimately be used
to optimise EV-mediated functional RNA transfer in pro-
spective therapeutics for gene delivery.
4.4. Usable knowledge for RNA delivery by EV-
inspired synthetic mimics
4.4.1. Preparation of RNA-loaded EV or EV-mimics
Since EVs are increasingly regarded as natural carriers of
nucleic acids, it is of interest to explore EVs as vectors for
delivering both endogenous as well as foreign genetic
material into recipient cells. For this approach, several
challenges remain, one of the most prominent being the
introduction of an RNA of interest into EVs. Several
reports describe loading procedures, based on electropora-
tion of EVs directly,[231–233] loading of EVs by virus-
infected cells,[234] or targeted embedding of specific
RNA-sequences into EVs via sequence-recognition
domains fused to vesicular proteins.[235] Although pro-
mising in concept, these loading procedures are in practice
less than ideal, either loading RNA with low efficiency or
showing artificially high loading caused by formation of
electroporation-induced nanoprecipitates.[61] In addition,
it is challenging to remove the nanoparticle-forming che-
mical transfection reagents from the EV preparation after
loading.
Even if the challenge of RNA loading is met, the
subsequent steps in functional delivery of RNA content
into the target cells present significant hurdles. Upon
intravenous injection, EVs are generally rapidly taken
up by cells of the mononuclear phagocyte system,
particularly in the liver and spleen. This limits the
distribution of EVs to other cell types. In addition,
not all target cells are accessible via the vascular
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lumen, as the endothelial barrier prevents extravasa-
tion. Only at sites of fenestrated or sinusoidal endothe-
lium, or at sites of increased permeability, can
extravasation be expected. Finally, specific recognition
of the target cell should be followed by appropriate
delivery of the RNA cargo in its cytoplasm.
In addition to natural EV-based delivery systems,
EV-mimics have emerged as alternative delivery sys-
tems.[236] The design of EV-mimics is inspired both
by understanding of the properties of synthetic lipo-
somes and by knowledge of the structure and function
of EVs. Since not all components of EVs may be
required for proper delivery, the synthetic mimics of
EVs could be developed through assembly of liposomes
having crucial components of natural EVs in order to
reduce structural complexity.[237] Although
Kooijmans et al. [237] have provided insight into
which EV components could be used to enhance the
drug delivery properties of EV-mimetics, EV compo-
nents that are essential for the assembly of functional
EV-mimetics remain to be identified.
In theory, the EV-mimics could be designed with
enhanced circulation time and increased specificity for
target cells. Such EVs could be applied for the cytoplasmic
delivery of wide variety of biomolecules such as oligonu-
cleotides, DNA, proteins and peptides.[238] In this regard,
modifying EVs with nanobody-PEG-lipids could poten-
tially protect the biomolecules loaded inside from macro-
phages and give the EVs high affinity for the receptor of a
particular target cell type. This prolonged circulation time
and target cell specificity could increase EV accumulation
in targeted tissues and may improve the cargo delivery.
[239] Most recently, Sato et al. [240] developed hybrido-
somes (hybrid EVs) by fusing their membranes with lipo-
somes, showing that it is possible to control the degree of
interaction between hybridosomes and recipient cells
through amembrane-engineering strategy. These develop-
ments will open up new avenues for developing improved
RNA delivery systems and may advance the field of
nanomedicine.
4.4.2. Delivering EV-RNA cargo: understanding
mechanisms of EV fusion with recipient cells
The fusion and entry of EVs into recipient cells may
follow several routes (Figure 3). The EV uptake mechan-
ismmay depend on the target cell type and recognition of
proteins or receptors present on the surface of both EVs
and on recipient cells, as well as environmental condi-
tions. Notably, the protein molecules present on both the
surface of EVs and on the plasma membrane of recipient
cells potentially modulate vesicle binding and uptake by
recipient cells. It has for example been shown that
heparin sulphate proteoglycans (HSPGs) on the plasma
membrane of the recipient cell efficiently regulate EV
uptake.[241,242] Furthermore, it was recently demon-
strated that various isoforms of integrins present on
tumour-derived EVs influence the uptake of EVs in an
organ-specific manner.[223] Environmental factors that
Figure 3. Extracellular vesicle uptake and cargo delivery in recipient cells. EVs may release their cargo into the cytosol through
direct fusion with the plasma membrane. Alternatively, EVs may be internalised via a variety of endocytic mechanisms, including
clathrin-dependent endocytosis, clathrin-independent endocytosis, macropinocytosis and phagocytosis. Subsequently, EVs are
transported into the cytoplasm in endocytic vesicles. These vesicles may proceed to scan the endoplasmatic reticulum (I), which
has been reported to be a site for translation and RNA interference. EVs may fuse with endosomal membranes after acidification to
release their RNA content (II), or be directed to lysosomes where they are degraded (III).
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influence EV uptake include temperature and radiation
exposure,[243] as well as pH conditions, which affect
direct fusion of EVs with the plasma membranes of
recipient cells.[244,245] Intracellular availability of ATP
in recipient cells has also been shown to affect EV uptake,
indicating that the internalisation of EVs into recipient
cells is an energy-requiring process.[246]
Different mechanisms of internalisation have been
described. In a classical way, EVs could enter cells via
clathrin-dependent endocytosis, micropinocytosis or
phagocytosis.[247] Additionally, EV uptake may also fol-
low the non-classical, lipid raft-dependent endocytosis
involving caveolin-mediated entry.[248] Interestingly,
Heusermann et al. [62] recently reported that purified
EVs labelled with GFP-CD63 surf filopodia of primary
human fibroblasts, before being endocytosed at the cell
basis in a process reminiscent to entry of specific viruses.
In the cytoplasm, internalised EVs particles establish
transient contact with the endoplasmic reticulum (ER)
before being eventually being trafficked to the lysosomal
compartment. Converging evidence indicate that ER is a
cellular nucleation site for RISC complex miRNA/siRNA
loading and targeting of mRNA.[136,249] As such, it
could be speculated that internalised EVs may deliver
their miRNA cargo in close proximity to the ER in
order to favour their loading into AGOs.
5. Conclusions and considerations
The EV-RNA research field has clearly progressed
since the previous ISEV workshop on EV-RNA held
in 2012. There is a better understanding of the hetero-
geneity of EV subpopulations and of non-EV RNA-
carrying structures that potentially contaminate EV
preparations and their distribution among different
body fluids. In addition, several factors influencing
sorting of RNA into EV have been identified and
experimental systems have been designed to address
functional transfer of EV-RNAs in vitro and even in
vivo. Nevertheless, the field continues to experience
numerous technical challenges: the large variety in EV
isolation procedures, the small size of EV and the
minute amounts of RNA that are recovered from
these vesicles, and biases in the analysis of these trace
amounts of RNA. In addition, it remains challenging to
obtain direct proof for the role of EV-associated RNA
Research question Considerations
• Does the EV preparation contain RNA-carrying 
contaminants (e.g. HDL, RNPs)?
• Is the RNA protected from protease + RNase 
treatment? 
• Which EV populations are represented? (donor 
cell, size, protein content)
• Detection of large and small RNAs? 
• Are the RNAs intact or fragmented?
• Do the RNAs contain nucleotide modifications 
that may interfere with analysis?
• Does content depend on 
activation/differentiation status of cells?
• Is it different in health/pathology?
• Can transfer be detected in vitro? in vivo?
• Does transfer of dyed EVs or EV marker 
proteins correlate with movement of RNA?
• Is the transferred EV-RNA also endogenously 
expressed by target cell?
• Does the EV-RNA modify mRNA levels or 
trigger other receptors (e.g. PAMPs)?
Is the extracellular RNA 
contained in an EV 
population?
What is the RNA content of 
the EV?
Is incorporation of the EV-
RNA of interest regulated?
To which cells is the EV-
RNA targeted?
Does the EV-RNA of interest 
modify target cell function?
Figure 4. Considerations for analysing the nature and function of EV-associated RNA. Overview of research questions aimed at unravelling
the nature and function of EV-RNA and considerations in addressing these questions, as discussed at the 2015 ISEV workshop on EV-RNA.
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in effects that EVs exert on target cells in vitro and in
vivo. As an overview of what was discussed at the 2015
research seminar on EV-RNA and to prepare research-
ers from inside or outside the EV field for working in
this area, we provide a list of important considerations
that could guide future experiments (Figure 4).
Furthermore, we provide a list of experimental details
(an updated version of the list provided in the previous
EV-RNA position paper [9]) that should be reported in
publications addressing the composition and function
of RNA associated to EV (Table 6). This checklist may
aid in augmenting the reproducibility of studies in the
EV-RNA field and may also be used by reviewers and
editors to aid the review process of articles in the EV-
RNA research field.
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Table 6. Checklist experimental details to be included in publications.
Step Parameters to be described
EV isolation
Cell culture Cell type
Confluency
Cellular activation/differentiation status
Use of EV-depleted serum (include depletion protocol) or serum-free medium
Cell viability
Mycoplasma test
Body fluid Health/disease status
Collection method (disposables, chemicals, procedure)
Removal of body fluid specific contaminants
Storage
EV isolation Differential centrifugation steps
Filtration steps
Size exclusion chromatography
Density gradient
Commercially available kits (e.g. chemical, column based)
EV quantification method
EV-RNA characterisation
EV-RNA sample preparation RNase/DNase/proteinase treatment of EV
Use of RNA spike
RNA isolation method /kit
RNA quantification method
Bioanalyzer profile of EV-RNA
Library preparation Enzymatic treatment to remove phosphates, caps, etc.
Method /kit for ligating adapters
Pre-amplification steps
Size selection steps
Bioanalyzer profile of library
Sequencing Platform
Maximum read length
Direction (paired or single end)
Number of cycles
Number of replicates (biological or technical)
Bioinformatics Pre-processing software (trimming/clipping, cut-off values)
Reference genome assemblies (release numbers)
Primary analysis software (alignment and mapping criteria)
Browsers and annotation tools
Normalisation methods and software
Statistical methods and tools for differential expression analysis
Validation Validation technique
Normalisation procedure; validation of reference genes
Deposition in database Name of database
EV-RNA functional analysis
EV-RNA transfer Target cell type and activation/differentiation status
Methodology (EV-RNA labelling, target cell RT-qPCR)
Quantity of EV per target cell
EV-RNA function Methodology (transcriptome analysis, functional read-out)
Endogenous expression levels of EV-RNA in target cell
Proof to attribute functional effects to the RNA component of EV
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